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“If you don´t like bacteria, you´re on the wrong planet” 
-Steward Brand 
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ABSTRACT 
Neonatal infections caused by extended-spectrum beta-lactamase (ESBL)-producing Gram-
negative bacilli are associated with high morbidity and mortality. In order to perform targeted 
preventive interventions against the impacts of antibiotic resistance in neonates, it is crucial to 
study colonization, infection and the spread of EPE-bacteria.  
Methods and results 
Study I. A prospective observational study where the proportion of intestinal colonization 
with EPE, their resistance pattern and risk factors of EPE-colonization were assessed in a 
neonatal intensive care unit in Ecuador. In total, 56% of the neonates were colonized with 
EPE. The strains found were ESBL-E. coli (ESBL-EC, 89%) and ESBL-K. pneumoniae 
(ESBL-KP, 11 %) and the main risk factor for colonization was length of hospital stay. Two 
of the isolated clones were epidemic and known to disseminate carbapenem-hydrolysing 
beta-lactamases. These results underline the necessity of implementing colonization 
surveillance and improved hygiene standards in this and similar neonatal care settings.  
Study II. A prospective cohort study where we analysed the ESBL-KP isolates in a neonatal 
outbreak of EPE and determined the duration of intestinal colonization of EPE in affected 
neonates (n= 14). The intestinal relative abundance of EPE was determined in each carrier. 
One fourth of the neonates were still carriers of EPE, two years after a NICU outbreak. The 
median length of colonization was 12.5 months. The low virulent but highly resistant ESBL-
KP strain ST101 persisted in 2/13 children. One patient was colonized with ESBL-EC at five 
years of age. No infant suffered from an EPE-infection during the 5-year follow-up. 
Study III. In this study, the findings in study 2 were extended by characterizing the 
resistance encoding plasmids using optical DNA mapping (ODM) combined with Cas9-
assisted identification of resistance genes. The method detected two plasmids; one small  
(80 kb) and one large plasmid (220 kb) in all ESBL-KP isolates. We found that  
the blaCTX-M-15 gene was located on the small plasmid and that this plasmid was stable in the 
ESBL-KP clone for two years. There was an unrelated acquisition of an ESBL-EC strain, 
contradicting plasmid transfer between KP and EC in this outbreak. ODM is a promising and 
rapid tool for surveillance and infection control in clinical settings. 
Study IV. In a population-based retrospectively matched cohort study, we investigated the 
incidence, mortality and bacterial characteristics of neonatal sepsis caused by Gram-negative 
bacilli (GNB) sepsis in Stockholm County during a 11-year period. The primary outcome 
was death before discharge and secondary outcomes were death within 5 and 30 days after 
sepsis onset. The cumulative incidence of GNB-sepsis was 0.35 cases per 1,000 live born and 
for early onset sepsis (EOS) 0.11 and late onset sepsis (LOS) 0.24 respectively. Case fatality 
rate was 5/33 (15%) in GNB-EOS and 26/74 (35%) in GNB LOS. Neonates with GNB-LOS 
were  3.9 times more likely (adjusted OR, 95% CI: 1.6-9.4) to die before discharge compared 
to the uninfected matched control group. Overall, 6.5% (7/107) of the isolates were 
multidrug-resistant. The incidence of both GNB-EOS and GNB-LOS was lower than 
reported in previous studies from other high-income countries comparable settings. Mortality 
in GNB-LOS remains high. The occurrence of acquired antibiotic resistance was low and did 
not change substantially over time.  
Conclusions 
A high proportion (56%) of the neonates at a NICU in a tertiary hospital in Ecuador, became 
colonized by EPE. These EPE included two clones of ESBL-KP that are known to 
disseminate carbapenemases. Infants that were colonized during an EPE-outbreak at two 
NICUs in Stockholm carried the same ESBL-KP for 26 months. There was no plasmid 
transfer between bacteria during the outbreak. During a 11-year period in Stockholm, Gram-
negative sepsis was rare but a major risk for neonatal mortality. 
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1 INTRODUCTION 
The human has evolved together with bacteria over a period of 400 million years. 
About one million newborns die due to bacterial infections during the first month of age and 
out of these infections, about 30% are estimated to be caused by antibiotic resistant bacteria 
(1). Antibiotics are the most commonly used drugs in neonates worldwide. 
Medicine has, in the last decade, undergone a paradigm switch from talking about killer 
microbes to talking about the microbes that we need for a good health. When a newborn 
infant needs support directly after birth and is admitted to a neonatal intensive care unit, the 
antibiotic paradox is present from the first second of life. The high risk of dying from a 
pathogenic and, in large parts of the world, resistant bacteria versus the negative impact of 
antibiotics on the normal microbiota is part of the paradox.  
Antimicrobial resistance (AMR) and antibiotic resistance (ABR) has affected both low-
income countries (LICs), low- and middle-income countries (LMICs) and high-income 
countries (HICs) for many years. The increase in ABR represents a major threat to child 
health as well as public health (2). The prevalence of multidrug-resistantorganisms varies 
geographically in healthcare settings.  
In 2015, the World Health Organization (WHO) identified ABR as one of the biggest threats 
to human health and as a key priority in reducing mortality due to infectious disease (3). 
MDRO infections are significantly associated with higher economic burden than infections 
with susceptible bacteria (4). In 2019, a collaboration between leading biopharmaceutical 
companies, the World Health Organization, the Wellcome Trust and the European Investment 
Bank resulted in the launch of the AMR action fund. The AMR action fund aims to bridge the 
funding barriers of late-stage antibiotic development in all countries and to bring 2-4 new 
antibiotics to the market before 2030.  
Outbreaks of MDRO that colonize hospital-admitted neonates, share some common 
characteristics: the time needed to identify the problem, the difficulties in identifying the 
source, the time to implement infection control measures, and finally, eradication of the 
bacteria (5). If it is known that an outbreak of MDRO is taking place in the neonatal intensive 
care unit (NICU) and what the characteristics of the causing strains are, the chance of treating 
a septic neonate increases. 
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When the work with this thesis started, the nature and development of the neonatal intestinal 
microbiome was not as widely studied as it is now. It was more commonly assumed that the 
uterus environment and the first fetal meconium were sterile and that the neonate gut was 
strictly colonized with bacteria after birth. Recently, data on the perinatal and infant 
microbiome has shown otherwise (6-9). However, the importance of microbial communities 
at different times in the developing fetus´s and infant´s life, is yet not fully understood (10, 
11). 
The ongoing research on the spread of ABR-bacteria is broad and making progress. Strategies 
for how to educate societies, individuals and health care personnel to reduce mortality from 
ABR-related infections is on the agenda of many countries. Understandingly, some of them 
have greater difficulty in achieving the set goals. One way to tackle the invisible threat posed 
by antibiotic resistance infections to neonates, is to look at the way it challenges neonates and 
their health care workers in different settings. This thesis contributes results from research 
studies carried out in both a LMIC and a HIC setting. 
How prevalent is neonatal colonization of ABR-bacteria, such as ESBL-producing 
Enterobacteriaeae (EPE), in neonates in a LMIC with high antibiotic use, limited infection-
control measures and low awareness of antibiotic resistance? This thesis presents results from 
a study in a tertiary university hospital in Ecuador, which was done in order to strengthen the 
indications for preventive work in NICUs and to raise awareness within the country and the 
Latin American region.  
The bacteria in the human microbiome are a highly important reservoir of antibiotic resistant 
genes. Since intestinal colonization of resistant Gram-negative bacteria is a critical step in the 
pathogenesis of invasive infections, the issue of duration of colonization is clinically 
important within NICU-settings. The question of duration of colonization is addressed in this 
thesis. 
Advances in neonatal intensive care in HIC have improved survival of extremely low birth 
weight infants and other critically ill newborns, who are highly exposed to nosocomial 
infections (12). These neonates do often have a long duration of hospital stay. We conducted 
a study to determine the incidence of Gram-negative bacterial (GNB) sepsis and the burden 
of ABR among neonates in the Stockholm region. We had a hypothesis that there was a low 
to moderate prevalence of GNB-sepsis but a high in-hospital mortality when the sepsis 
causing bacteria were EPE. We wanted to bring data into the discussion about whether or not 
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our sepsis care and our antimicrobial stewardship was efficient during the neonatal period in 
our region. 
For the neonatologist, to make a good assessment of the specific EPE-strain that is causing 
the NICU outbreak, the new sequencing methods are helpful. It is a fact though, that they take 
a considerable amount of time and in a situation where the bacteria are already ahead of us, 
time is an important factor. In this thesis, we address plasmid-mediated spread of resistance 
in neonatal intensive care settings and optical DNA mapping (ODM) as a tool to rapidly 
diagnose it.  
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2 BACKGROUND 
2.1 BACTERIA 
Bacteria were one of the first living organisms on earth. They are primitive one-celled 
organisms with no nucleus and free-floating genetic material in their cytoplasm. The bacteria 
store their DNA in the nucleoid (chromosomal) and in DNA molecules in the cytoplasm 
(plasmids).  
Bacteria reproduce by dividing into two identical daughter cells. They are classified in 
divisions (phyla), subdivisions (subphyla), subgroups, families and genuses. Another 
classification of bacteria is whether or not the bacterium has one or two membranes. These 
two groups have different responses to a color staining procedure called Gram-staining, with 
some exceptions. The Gram-positive group of bacteria (GPB) has one membrane 
(monoderm) and the Gram-negative group (GNB) has two (diderm). The Gram-staining 
technique is used to group bacteria based on how their cell wall is constituted. The thick 
peptidoglycan layer are stained purple in GPB while the GNB have a thinner peptidoglycan 
layer in the cell wall and are not stained. ). Not all bacteria have a cell wall.  Bacteria have 
different shapes and are as well classified into five groups according to their shapes: rods-
shaped (bacilli), spiral (spirilla), comma (vibrios), spherical (cocci) or corkscrew 
(spirochaetes). Gram-staining and shape description are rapid tools to group species into 
subdivisions of the bacteria. The cell structure of a bacteria is depicted in figure 1.  
 
Figure 1. Cell structure of Gram-positive bacteria and Gram-negative bacteria.  
Modified and with permission to republish from American Society for Microbiology. 
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Bacteria produce bioactive substances, so called “natural products”, which have antibacterial 
activity. These substances from antibiotic-producing microbes have been used to prevent and 
treat disease for more than 2,000 years and eventually this knowledge led to the synthetic 
production of the modern antibiotics (13-16). The Gram-negative (diderm) bacteria have an 
outer membrane composed of a thick lipopolysaccharide layer. One hypothesis concerning 
bacterial evolution has proposed that this outer cell membrane has evolved from monoderm 
bacteria to diderm bacteria because of the natural antibiotic selection pressure (17).Thus, the 
thick outer membrane of the Gram-negative bacteria provides additional protection from the 
surrounding environment. 
Bacteria have, as well, responded to the introduction of antibiotics by developing several 
other protective capabilities such as; the production of specific antibiotic efflux pumps, the 
downregulation of porins to decrease the permeability of antibiotics through the cell 
membrane and the production of enzymes that degrades the antibiotic structure. The 
virulence of a bacteria is its ability to damage the host. 
In 2008, a group of bacteria were defined as the ESKAPE pathogens. They are more capable 
of “escaping” the action of antibiotics than others and are problematic in terms of ABR. The 
ESKAPE group consists of Enterococcus faecium, Staphylococcus aureus (SA), Klebsiella 
pneumoniae (KP), Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA) and 
Enterobacter spp (18, 19). 
In this thesis, I will address how the clinically relevant Gram-negative bacilli KP and 
Enterobacter spp, from the family Enterobacteriaceae, can affect the neonate. The family 
Enterobacteriaceae is a large group within the group Gammaproteobacteria and phylum 
Proteobacteria. 
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2.1.1 Plasmids 
Plasmids are circular, double-stranded large DNA molecules (1-1,000 kb) in the bacterial 
cytoplasm. These genetic elements are extrachromosomal and not essential to maintain basic 
bacterial functions. However, they play a crucial role when it comes to adapting to new 
environments and to carry and spread resistance genes. The plasmid replicates its DNA 
autonomously and has the ability to acquire and insert new genetic material into its sequence 
or drop genes that no longer are necessary. Many of the important human pathogenic bacteria 
within the Enterobacteriaceae family transfer plasmids carrying resistance genes (20).  
The process that transfers plasmid DNA between bacteria to another is called conjugation. 
Conjugation is mediated by a transport system that includes a relaxase protein hooking on to 
the plasmid DNA on the cytoplasmic side and a 12-protein complex transport system which 
forms the transport channel and the pilus (fimbriae) in the bacteria. The DNA-relaxase 
complex is then transported through the pili into the recipient bacterial cell (21). Plasmids are 
classified in a number of ways. One traditional classification is into incompatibility groups 
(Inc groups). Plasmids in the same Inc group share the replication machinery and interfere 
with each other´s replication. Plasmids in different Inc groups can coexist stably (22). 
 
2.2 ANTIBIOTIC RESISTANCE 
2.2.1 An historical glance 
“The thoughtless person playing with penicillin treatment is morally responsible for the 
death of the man who succumbs to infection with the penicillin-resistant organism” 
-Sir Alexander Fleming 1945  
Antibiotic resistance is a natural phenomenon that began to accelerate almost a century ago, 
when antibiotics came to be the foundation of modern medicine for treating bacterial 
infections (23). ABR is driven by many factors that range from poverty to poor policy 
implementations. The golden age of antibiotics was 1950-60. Figure 2 shows the sources of 
the origin of the antibiotics, when resistance against them was found and some hot spots in 
neonatology in the same timeline.  
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Figure 2. Timeline showing the decade that new antibiotic was developed and reached the clinic. It shows the 
source of origin were green=actinomycetes, purple=other bacteria, red=penicillin, orange=synthetic products. 
The blue boxes indicate some important years in the development of neonatal care. Modified after permission 
from Current opinion in Microbiology, Hutchings et al. 
 
The WHO has identified a list of priority pathogens as highly important pathogens for future 
research on new treatment methods. ESBL-producing and carbapenemase-producing 
Enterobacteriaceae are included in the critical (priority 1) group as highly important 
pathogens for future research on new treatment methods. The global spread of ABR in Gram-
negative bacilli is one of the largest concerns because of their ability to confer resistance to 
carbapenems which have, until lately, been the drug of choice when treating MDR-infections. 
At this point in time, 1.5 million people in the world die every year of antibiotic resistant 
infections. A UN prognosis predicts 10 million deaths due to ABR annually, in 2050. 
 
2.2.2 Antibiotic mechanisms and bacterial mechanisms of defense  
All antibiotics have one of the following mechanisms of action against bacteria: inhibiting the 
bacterial cell wall synthesis; preventing bacteria from synthesizing proteins; or preventing 
bacteria from duplicating genetic material. Beta-lactam antibiotics include penicillins, 
cephalopsporins, monobactams and carbapenems. They are bactericidal and inhibit the 
biosynthesis of the cell wall. Broad-spectrum beta-lactam antibiotics are mainly used to treat 
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severe Gram-negative bacterial infections. The clinically most significant mechanism of 
resistance among Gram-negative bacilli is their ability to produce Extended-Spectrum Beta-
Lactamases (ESBL). ESBLs are enzymes that, by cleaving the amide bond in the beta-lactam 
ring inhibit multiple classes of beta-lactam antibiotics, and in some cases all beta-lactams 
(24). The beta-lactamase in GNB is excreted between the cytoplasmic membrane and the 
outer membrane, called the periplasmic membrane. The ESBLs are classified into four 
classes, A to D.  
Of all ESBLs, the CTX-M beta-lactamases are the most widespread enzymes (25).  
The CTX-M family consists of about 40 enzymes which can be divided into five different 
phylogroups, or clusters, and each of which contain a number of plasmid-mediated CTX-Ms 
are included. For example, the CTX-M group 1 includes six plasmid-mediated CTX-Ms (26). 
In 2008, the New Dehli Metallo beta-lactamase (blaNDM-1) was first found (27). This 
carbapenemase inactivates the carbapenems, the antibiotic class that was developed to 
overcome beta-lactamases.  
 
2.2.3 Plasmid-mediated antibiotic resistance 
ABR evolves constantly, and traditionally the epidemiology of resistant bacteria has been 
investigated with strain typing to document clonal spread. One reason for the successful 
dissemination by EPE, in recent years, is the result of the evolution and horizontal spread of 
beta-lactamase genes that are located on plasmids. CTX-Ms were originally chromosomally 
encoded beta-lactamases in the Klyvera spp but did later mobilize on to transferable plasmids 
in Enterobacteriaceae. ESBL genes are the most frequently described genes encoded on 
plasmids. Various plasmids are associated to different gene classes i.e IncI are mainly 
associated with ESBL-genes. (22) 
Resistance gene transfer via plasmids can result in generation of novel multidrug-resistant 
strains that are not clonally related and therefore the traditionally used epidemiological 
methods are not sufficient to detect nosocomial transmission. Traditional characterization of 
plasmids requires several different, time-consuming techniques, such as S1/PFGE, PCR and 
Southern blotting (28). 
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2.3 ENTEROBACTERIACEAE 
The family Enterobacteriaceae is large and consists of rod-shaped, non-fermenting, 
facultative anaerobic Gram-negative bacteria. Some of them can be found in soil and water 
and some of them are a part of the human intestinal microbiome. The most common 
Enterobacteriaceae are the pathogens Escherichia coli (EC) and Klebsiella pneumoniae (KP) 
which can cause severe infections but can also be commensals.  
2.3.1 Escherichia coli 
There is a great diversity of pathogenicity within the EC-species. EC is usually a non-
pathogenic member of the commensal intestinal microbiome and the majority of the EC have 
low-virulence. In the last 15 years, resistant strains of EC have become increasingly 
prevalent. These strains are more virulent and give EC the ability to overcome host defenses 
and cause infections like sepsis, urinary tract infections and diarrhea. EC are classified by 
their serotypes (O, K, H), their phylo groups (A, B1, B2, D) and their sequence types (STs) 
(35, 36). Bacterial characteristics and behavior differ between each phylo group. The 
phylogroups A and B1 are assumed to be low-virulent and therefore commensals. Extra 
intestinal infections (ExPEC) are mainly caused by phylogroup B2 and D and are also 
predominant in neonatal sepsis. Phylogroup B2 is associated with multiple virulence genes 
and longer duration of intestinal colonization compared to the other phylogroups (37, 38). 
The virulence factors in ExPEC are capsules (K1), toxins (hemolysin), toxin transporters (sat, 
vat) adhesins (pap, fimbriae) and iron invasion of endothelial brain protein (ibeA). When 
ExPEC are described by multi-locus sequence typing (MLST), it has been shown that ST131, 
ST 69 and ST 117 seem to be responsible for a large proportion of the invasive infections. 
The leading serogroup is O1, which is the leading cause of sepsis in pediatric patients (38). 
In EC, blaCTX-M 15 is the most common and globally disseminated ESBL-variant.  
 
2.3.2 Klebsiella pneumoniae 
KP was first described in 1882 and is the clinically most important Klebsiella species. KP is a 
colonizer in mammalian mucosal surfaces (mostly in the gastrointestinal tract and the 
respiratory tract) and is also found in water, plants and soil. Immunocompromised patients 
are particularly susceptible to KP. KP is, after EC, the second leading cause of GNB- sepsis 
in a pediatric population (29). The pathogenicity of KP is linked to the presence of virulence 
factors, such as the capsule, the lipopolysaccharides (LPS), the siderophores and the fimbriae 
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(30). These virulence factors appear to facilitate the initial colonization of the mucosal 
surface of the host, and then to persist and infect the host. KP have 78 different capsular 
types, where K1, K2, K5, K54 and K57 are associated with invasive infections of KP. The 
capsule contributes to the formation of biofilms and biofilm formation is an important 
strategy among KP strains to resist antibiotic treatment (31, 32). 
Most antimicrobial resistance in KP results from resistance carrying plasmids, but this species 
is also intrinsically resistant to ampicillin due to the presence of SHV beta-lactamase. 
Nosocomial isolates of KP often carry plasmids with resistance genes and not so often 
virulence plasmids. Nosocomial KP-strains are therefore more often resistant to antibiotics, 
compared to the KP-strains that are spread in the community (33). Some high-risk clones (ST 
15,48, 101, 147 and 383) of KP, have been described carrying a “hybrid resistance” which 
means that they feature both resistance -and virulence genes of major clinical concern (34). 
 
2.4 METHODS FOR DIAGNOSING EPE 
2.4.1 Phenotypic confirmation 
Rectal swabbing is a well-known and often used technique to collect samples to confirm 
intestinal ESBL-colonization. Detection of the ESBL enzyme in Enterobacteriaceae involves 
two phases, namely screening and confirmation. 
Firstly, the bacterial samples are plated on selective cephalosporin agar to screen for reduced 
sensitivity. Cefpodoxime or cefotaxime and ceftazidime are normally used in this first step. 
(39). Secondly, there is a phenotypic confirmatory test, such as combination disk testing or 
double disk synergy testing, both of which demonstrate that the beta-lactamase can be 
inhibited by a beta-lactamase inhibitor, such as clavulanic acid. (40). The confirmation can as 
well be automated by VITEK 2 (bioMérieux).  
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2.4.1 Genotypic confirmation  
To determine the relatedness between pathogenic bacteria, pulsed-field gel electrophoresis 
(PFGE) was for a long time considered the gold standard method. In later years, more 
automated sequence typing methods to investigate evolutionary relationships among bacteria 
have been introduced, such as multi-locus sequence typing (MLST) or core gene MLST 
(cgMLST). These methods are normally applied on sequence data from whole-genome 
sequencing (WGS). MLST is a widely used method that is based on characterization of 
bacterial strains by their unique allelic profile in the DNA sequence variations in 7 
housekeeping genes. The principle of MSLT is PCR amplification and DNA sequencing. The 
MLST technique was, in 2014, extended to a cgMLST protocol for KP that targets 694 core 
genes. This method is used to define clones with higher resolution and how they aggregate 
into clonal groups (CGs) (41). WGS is increasingly used in place of PCR-based sequencing. 
In WGS, the sequence data includes both chromosomal and plasmid DNA. Single nucleotide 
polymorphism (SNP) genotyping is a typing method of to measure genetic variations. A SNP 
is a mutation of a single base pair in the bacterial DNA.  
 
2.4.3 Optical DNA-mapping of plasmids  
In optical DNA mapping (ODM), sequence information is obtained for single large DNA 
molecules, with a resolution of around 1 kb. This method is well suited to determine the 
number of all large plasmids in the bacterial cell and to characterize them by size and by their 
unique barcode. 
The plasmid barcode can be used to identify spread of previously unknown plasmids between 
different strains and species of bacteria (42, 43). Furthermore, previously sequenced plasmids 
can be identified by comparing experimental barcodes with theoretical barcodes of thousands 
of plasmids within the NCBI public database (44). 
Labeling of the DNA molecules for ODM can be done in different ways (45). We here use 
competitive binding of fluorescent molecules, where fluorescent YOYO-1 and non-
fluorescent netropsin are added to the plasmid DNA. The YOYO-1 molecule can bind to both 
AT-rich and GC-rich regions of the DNA-molecule while netropsin is AT-specific and 
therefore competes with YOYO-1 for the AT-rich regions (46). This results in an emission 
intensity variation along the DNA molecule that reflects the underlying sequence, where AT-
rich regions are dark and GC-rich are bright, a DNA barcode (figure 3). 
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Figure 3. The principle of optical DNA mapping via competitive binding of YOYO and Netropsin to plasmid 
DNA. 
 
An extension of the ODM assay is to use the CRISPR/Cas9 system to determine on which 
plasmid a specific (resistance) gene is located (47). Clustered Reguarly Interspaced Short 
Palindromic Repeats (CRISPR ) and CRISPR-associated protein 9 (Cas 9) is a adapted from 
the genome editing system in bacteria (216). The Cas9 enzyme is guided to the specific DNA 
site by a guide RNA g(RNA) and produces a double-stranded break at the site of interest, in 
our case where the resistance gene is located. The cuts will occur at the same position along 
the sequence and is therefore site-specific. If the double-stranded break is caused by light, it 
will appear at random sites along the DNA sequence (figure 4). 
 
Figure 4. Cleavage of the plasmid by Cas9 or light induced. 
 
To visualize the variation in emission intensity along the plasmid, the plasmids need to be 
stretched and linearized. This can be done by in several ways (48), but here we stretch the 
plasmids by forcing them into nanochannels by pressure. Using a fluorescence microscope, 
an image is then taken of the linearized plasmid in the nanochannels. The images of these 
one-dimensional intensity profiles are stacked underneath each other to form a kymograph. 
The kymograph is then aligned and when the mean value of each column has been calculated, 
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an average emission intensity profile for the plasmid is obtained, the DNA barcode. To obtain 
a consensus barcode, an average barcode from many plasmids are averaged. A flowchart of 
ODM can be seen in figure 5. 
 
Figure 5. Optical mapping as a rapid method for characterization of bacterial plasmids. The plasmids are cut 
by Cas9 at the site of the resistance gene and labeled with fluorescent and non-fluorescent molecules. The 
plasmids are forced into in nanochannels and stretched linear. The underlying DNA sequence of the plasmids is 
imaged as emission intensity profiles and time traces (kymograph) represent the optical maps and gives each 
plasmid a unique barcode and ID.  
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2.5 NEONATES 
 
The neonatal period is defined as the first 28 days after birth. A normal pregnancy lasts about 
40 weeks. Preterm birth is classified, based on gestational age in weeks (GW), into extremely 
preterm (less than 28 GW), very preterm (less than 32 GW) and moderate to late preterm (32-
36 GW). Infants born extremely preterm and very preterm need, to a variable degree, 
supportive care at a NICU.  
Globally, around 15 million babies are born preterm and complications due to prematurity are 
one of the leading causes of death under five years of age (49). The worldwide incidence of 
preterm birth is estimated to be 11%, ranging between 18% in Malawi and 5% in northern 
Europe (50). In Sweden 2018, the incidence of preterm born infants was 6,1% which was 
about 7000 births in total. The same year in Ecuador, preterm infants were 6.8% of all born 
and registered infants.  
 
2.5.1 The neonatal defense against infections 
The preterm neonate has an immature skin barrier and an intestine with a lower barrier 
function and underdeveloped peristalsis compared to term neonates. This makes the skin 
easier to perforate and the intestine a potential site of infection and inflammation. Bacterial 
translocation, from the gastrointestinal tract to extraintestinal sites, is more common in the 
premature infant than the term born infant (51, 52).  
The most immature neonates have an immune system that is characterized by a low pool of 
neutrophils and during sepsis there is rapid exhaustion of the bone marrow reserve (53). 
Transplacental antibodies (IgG) play an important role in the first line defense against 
bacteria and low IgG levels are associated with late onset sepsis (54). Opsonisation, coating 
bacteria with antibody and complement, is an important step in the process to clear bacteria 
from blood and tissue. Impaired opsonisation is associated with low gestational age (55, 56). 
Administration of immunoglobulins (IVIG) that can stimulate complement activation, 
opsonic activity and antibody-dependent cytotoxicity, have had no prophylactic effect on 
neonatal sepsis (57). IVIG treatment in sepsis and suspected sepsis in neonates did not reduce 
mortality in a large multi-center trial (58).  
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The results of recent general discussions on the topic whether the neonatal immune system is 
defective or not, have indicated that the neonatal immune system responses are fully 
competent in some instances and lower in others (59). Neonatal immunity is suggested to not 
be simply immature, but actually regulated for the early stage of postnatal life. The first 
months of life are set to be an important time window for the immune system, and the gut 
microbiota and the immune development in infancy are tightly linked together (60-62).  
 
2.6 HUMAN MICROBIOTA 
The human microbiota is highly diverse and includes all microbial organisms that live in and 
on the human body. The number of bacterial cells in this complex ecosystem, is often 
estimated as 10 times as many microbial cells compared to human cells. This estimation has 
lately been questioned and the ratio has been approximated to be closer to 1:1 (63). The 
human microbiota consists of many phyla of bacteria and the most common are 
Bacteroidetes, Firmicutes, Actinobacteria, Verrucomicrobria, Fusobacteria and 
Proteobacteria. 
The microbial communities (i.e. microbiota) in different parts of the body differ widely and 
play a functional role in the physiology of humans. The balance between protective 
commensals and pathogens is important. The commensals inhibit pathogen growth, 
metabolize drugs to active metabolites, digest carbohydrates, produce vitamins, stimulate and 
modulate immune function, stimulate gut motility, and maintain a barrier function and 
stimulate epithelial repair. There is a specific microbiome for the mouth, skin, urogenital 
tract, respiratory system, intestinal tract, breast milk and placenta (64). Most of the intestinal 
microbes are confined to the distal ileum and colon. The abundance and the species change 
over the gastrointestinal tract.  
Changes in the composition of the microbiota occurs naturally during life, such as from 
infancy to adulthood and in pregnancy. Many external factors can change the microbiota 
which can be harmful (called dysbiosis) and result in long-term consequences like auto-
immune diseases. Recent studies suggest that dysbiosis in infant and child gut microbiota is 
associated with childhood asthma, coeliac disease, type 1-diabetes mellitus and atopy (65-
68). 
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2.6.1 Neonatal gut microbiota 
The hypothesis that the fetus, uterus and placenta are germ-free environments has been 
challenged and further studied in recent years. Diagnostic methods such as next-generation 
sequencing (NGS), have established that the fetus does not reside in a totally sterile 
environment and subsequently that the meconium of neonates is not sterile. Recent studies 
have shown the presence bacterial DNA in placenta, meconium and amniotic fluid (6-9).  
One study characterized a unique placental microbiome and showed a non-commensal 
microbiome with Firmicutes, Tenericutes, Proteobacteria, Bacteroidetes and Fusobacteria. 
Antenatal urinary tract infection (UTI) in the first trimester and preterm birth <37 GW was 
associated with the same bacteria later found in the placental microbiome(7). Another study 
showed that the features of the bacteria in the microbiome of the placenta and amniotic fluid 
were the same as in the infant´s first meconium. This suggests a transfer of microbes in the 
foeto-maternal interface. At three days of age, the infant´s intestinal microbiota resembled the 
bacteria detected in colostrum (8). Gosalbes et al implies that the neonatal gut can be a 
reservoir of antibiotic resistant genes even before birth (69). It is more common to find 
bacteria that colonize the basal plate of the placenta from preterm deliveries than term 
deliveries (70). 
These small recent studies suggest that there is a pre-colonization phase of the fetal intestine 
in utero, but the presence of bacteria is only an association and large perspective studies have 
not been done. The importance of this is so far is not known. However, there is strong 
evidence that the initial colonization (phase two) is clinically important and influences 
immune development in the neonatal gut (71). The colonization phases of the infant are 
presented in table 1.  
The development of the gut microbiota in preterm infants shows that neonates can change the 
abundance of dominating bacteria in their gut microbiota within days and that the microbiota 
composition and bacterial load is strongly associated with postnatal age (72). Extremely 
preterm-born neonates often spend a long time in the NICU. A study of the neonatal 
microbiome in the NICU shows that the specific microbiome of one neonate was found in 
environmental bacterial samples, despite regular cleaning, and suggests that hospitalized 
neonates and their caregivers shape the microbiome of the NICU. In other words, each 
room/caring area has its own unique neonatal microbial fingerprint by the time the patient has 
been discharged (73).  
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Table 1. Phases of the intestinal colonization of the infant. Modified from Walker et al "The importance of 
appropriate bacterial colonization of the intestine in newborn, child and adult health, Pediatric Research 2017. 
 
In a cohort, were the median gestational age of the study participants was 25-31, the most 
common bacteria (>50% of bacteria) in the gut microbiota were Staphylococcus, 
Enterococcus, Enterobacter and Bifidobacteria. With increasing postnatal age, the pattern 
changed from Staphylococcus-Enterococcus domination to the Enterobacter and later 
Bifidobacteria- dominated microbiota (72). A gut microbiome without dysbiosis stabilizes 
around 2-3 years of age (74). Premature neonates in the NICU have an intestinal bacterial 
composition consisting of more GNB compared to full-term breast-fed neonates who mainly 
harbor less harmful Bifidobacteria in their intestines (75).  
  
Phases of intestinal 
colonization of the infant 
intestine
Clinical conditions with an atypical (dysbiotic) intestinal 
colonization in the per inatal per iodNormal conditions
Phase one
Intrauterine period
Phase two
1st week of life
Phase three
2 weeks- 4 months
Phase four
2 weeks- 4 months
Phase five
1 to 3 years
Some studies suggest that the fetus can 
become exposed to maternal microbiota by 
trans- placental passage into amniotic fluid.
The neonate ingests vagina/colonic 
microbiota in birth canal. (Full term, 
vaginal delivery)
Dysbiosis in maternal intestine (use of antibiotics, 
obesity) can affect transplacental passage of microbiota 
to the amniotic fluid.  So far, only associations in mice. 
More studies needed.
Sparse colonization due to dysbiosis inmaternal 
intestine, premature delivery, perinatal prophylactic 
antibiotics, ceaseran delivery
The colonization process modifies 
slightly by introduction of feeding.
Introduction of oral feeding
The period of weaning to solid foods
Infant recieves table-food and the gut 
microbiome resembles an adult 
intestine. Diversity of bacteria >1000 
species
The colonization is delayed and incomplete until four 
to six years
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2.6.2 Factors that influence the neonatal gut microbiota  
Maternal microbiome 
The early neonatal gut microbiota mirrors the microbiome of the mother. In the normal 
pregnancy, the maternal intestinal microbiome changes most significantly between first and 
third semester. The species diversity decreases and the counts of specific microbes increase in 
the third trimester, Actinobacteria and Proteobacteria being the species most commonly 
increased. In a healthy mother, the vaginal microbiome increases the abundance of the lactic 
acid producing bacteria, Bifidobacteria, towards the end of the pregnancy. A healthy 
intestinal microbiome has a high diversity of species and a healthy vaginal microbiome has 
less diversity (76). Dysbiosis in the vaginal microbiome, with a increased vaginal diversity 
and decreased intestinal diversity, is associated with preterm birth, but no specific vaginal 
species have been clearly associated with premature birth (76). 
Feeding  
The Bifidobacteria from the mother play an important role in the healthy microbial ecosystem 
of the neonatal intestine. Human and bacterial evolution have produced the most perfect 
composition of the breast milk for the newborn infant. Bifidobacteria metabolize the human 
milk oligosaccharides (HMO) into lactate and acetate to lower the pH in the intestine. This 
provides a “colonization resistance”, a strategy to limit opportunistic pathogens from growing 
(77, 78). The HMO are oligosaccharides that have no nutritional value for the baby as they 
are only digested by the gut bacteria. These HMOs interact and inhibit the binding of 
pathogenic bacteria to the host cells receptors (79, 80).  
Human milk also contains microbes, such as Streptococcus spp, Staphylococcus spp, 
Cutibacterium and lactic acid bacteria. Less risk for colonization by EPE- strains has been 
shown to be associated with breastmilk and HMO formula feeding (77). Cow´s milk formula, 
on the other hand, is associated with a higher abundance of GNB in the neonatal gut.   
In addition to Bifidobacteria, the gut microbiome of a healthy infant is also dominated by 
Lactobacillus species and Enterobacteriaceae species (11). These species stimulate specific 
IgA-antibodies in in the intestinal lumen and also inhibit pathogens from adhering to the 
intestinal wall, becoming a part of the intestinal “barrier effect” against invasive infection 
(81, 82).  
Lactobacilli with antimicrobial properties in the oral microbiota are more common in 
breastfed infants compared to formula-fed infants (83, 84). A strategy of feeding probiotics 
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containing Bifidobacteria to prevent neonatal late onset sepsis (LOS) has been suggested, in 
theory, to increase the intestinal mucosal barrier in order to prevent bacterial translocation 
into the blood and exclude potential pathogens (78, 85). Early enteral feeding is also 
proposed to prevent atrophy of the intestinal mucosa and therefore establish a faster healthy 
flora and mucosal immunity (86).  
Probiotics with Bacteroides infantis have shown to decrease the abundance of 
Enterobacteriaceae and the bacterial antibiotic resistant gene load in the infant gut in 
breastfed infants (87). The low pH is suggested to be the key to colonization resistance. A 
meta-analysis of 20 randomized controlled trials show that probiotics decrease severe (88). It 
is also stated that probiotics alone are not enough to maintain the complex homeostasis of the 
neonatal gut microbiota. Indeed, a holistic approach to the microbiome is needed (89). 
When breastfeeding ends, the intestinal microbiota shifts to a more mature gut microbiota and 
the abundance of Firmicutes increases (90). Later the microbiome changes to include bacteria 
that facilitate the digestion of nutrients from solid food (90, 91).  
Birth mode  
Birth mode is a factor that strongly affects the gut microbiota in neonates (92). The gut 
microbiome differs in composition and diversity between infants born by caesarean section 
(CS) and vaginal delivery (52). The lack of colonization by the fecal and vaginal microbes 
results in a lower diversity and a decreased abundance of Bacteroides, Bifidobacterium and 
Lactobacillus in neonates born by cesarean section (93-95). Full term neonates are more 
dominated by oral and skin microbes in the gut microbiota after CS and Lactobacillus spp is, 
as mentioned, more often seen in the vaginally-born neonates. CS is correlated with a higher 
abundance of Staphylococcus spp early in life (96).  
The gut microbiota of extremely preterm neonates with a long hospital stay, clinically 
delayed oral feedings, prolonged parenteral nutrition and long duration of antibiotic therapy, 
have shown to predominantly consist of KP, EC, Staphylococcus epidermidis, Enterococcus 
fecalis, and Enterobacter cloacae (97). Some of these species are the most common 
pathogens in LOS (98). 
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Antibiotic treatment  
Studies show, that neonates that do not receive antibiotics develop a more diverse microbiota 
(91). Even a treatment period with antibiotics of less than 3 days has shown decreased the 
abundance of Bifidobacterium in the three subsequent weeks. After 5 days of antibiotic 
treatment, the Bifidobacteria abundance remains decreased until 6 weeks postnatally. After 
anti-fungal treatment, there were lower levels of Bifidobacterium as well (93). 
Two studies have showed an association between intra partum antibiotic prophylaxis (IAP) 
for Group B Streptococcus (GBS) and delayed in colonization of Actinobacteria and  
decreased in abundance of Bifidobacteria (99, 100).  
Early antibiotic treatment is, due to dysbiosis, associated with an increased risk of the feared 
neonatal complication of necrotizing enterocolitis (NEC) (101). A high abundance of 
Enterobacter, has been shown in the gut microbiota in premature born neonates after 
antibiotic treatment. A common belief is that the impaired intestinal barrier leads to a 
translocation of gut bacteria and bacteremia. Exposure to antibiotic treatment of more than 10 
days, has been associated with an three-fold risk of developing NEC (102). 
Studies on adult microbiota and antibiotic treatment have shown a correlation between 
antibiotic treatment and changes in glucose metabolism, development of diabetes type 2 and 
bodyweight regulation and as well a change in abundance of microbiota for several months 
after the treatment period (103-105). 
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2.7 NEONATAL SEPSIS 
2.7.1 The neonatal sepsis definition 
Neonatal sepsis is the inflammatory response of a systemic invasive bacterial, viral or fungal 
infection that affects the neonate during the first 28 days of life. Early-onset sepsis (EOS) is 
defined as sepsis presenting within 72 h after birth and late-onset sepsis (LOS) occurs 
between 72 h and 28 days of life (106). To make a definite sepsis diagnosis can be difficult in 
the neonatal period (107). The balance between the commensal intestinal bacteria and the 
invasive pathogen is complex. The clinical signs of sepsis are non-specific and other non-
infectious symptoms can be similar to those of sepsis.  
At the International Pediatric Sepsis Consensus Conference in 2005, a definition of neonatal 
sepsis was set. It included the systemic inflammatory response syndrome (SIRS)-criteria 
together with proven or suspected infection (108). Another hypothetical sequential organ 
failure assessment (nSOFA)-score has suggested a definition neonatal sepsis in 2018. The 
nSOFA algorithm includes six items with scores from 0 to 3; respiratory status, 
cardiovascular status, renal function CNS function, platelet counts and absolute neutrophil 
counts.  
The inclusion of white blood cells has been questioned because of its poor predictive value 
(109). There are ongoing discussions regarding a definition of neonatal sepsis, but at this 
moment there is no consensus defined (110, 111). Neonates with clinical symptoms as SIRS 
and no detected bacteria in the blood-culture are diagnosed as “suspected sepsis”. Most data 
on neonatal sepsis only include culture-confirmed cases of neonatal sepsis.  
 
2.7.2 Incidence and mortality of neonatal sepsis  
In 2018, 2.5 million children died in the first month of life. The numbers of these neonatal 
deaths are approximately 7,000 deaths every day. Neonatal deaths account for almost half 
(47%) of all global under-five deaths (112). Neonatal infections cause more than one third 
(36%) of neonatal deaths worldwide and neonatal sepsis remains the leading cause in LIC 
and LMIC (113). Neonatal sepsis due to EPE is associated with a high morbidity and 
mortality and the number of deaths due to all antibiotic resistant bacteria is estimated as 214 
000 cases per year (1, 114-116).  
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Approximately 58,000 of these neonates die in India (117). One of the Sustainable 
Development Goals, promulgated in 2015, aims to decrease preventable deaths of newborns 
and children under 5 years of age by 2030. All countries are aiming to reduce neonatal 
mortality to at least 12 per 1,000 live births, and under-5 mortality to at least 25 per 1,000 live 
births (118). 
The incidence of neonatal sepsis is 1-4 per 1,000 live births in HIC (119). In a review of 32 
studies that reported neonatal bloodstream infections in LIC the neonatal sepsis rate is 3-20 
times higher than in HIC. For example, the incidence of neonatal sepsis is 30-40/1,000 in the 
African region and 12/1,000 in the regions of the Americas.  
Sepsis related mortality in neonates also depends on the causative agent. The mortality for 
GPB- LOS has in large studies been approximated to 6-8% and is suggested not to differ 
from the infants with suspected sepsis (8%)(120). GNB-sepsis is less prevalent than GPB-
sepsis, but is associated with higher mortality (19-36%) (120-122). The case fatality rate of 
GNB-LOS in very low birth weight (VLBW) infants that were admitted to 313 NICUs in 
North America between 1997 and 2010 was 21% (123). Treatment failure of neonatal sepsis 
is associated with increased mortality, longer hospital stay and higher costs (12, 124, 125).  
Neonatal sepsis (both GNB and GPB) is associated with neonatal morbidities like white 
matter injuries and subsequent neurodevelopmental sequele, bronchopulmonary dysplasia 
(BPD), NEC and retinopathy of prematurity (ROP) (98,119,121,131)  
Incidence and mortality of neonatal sepsis in Sweden and Ecuador 
Two studies from the western area of Sweden between the years 1975-1986 and 1987-1996, 
show the incidence of neonatal sepsis as 2.8-3.7/1,000 live births. The case fatality decreased 
in the second study to 9% from the previous 15% (126, 127). A recent study from the same 
area shows a significant decreased incidence of EOS from 1,4/1,000 live births (1997-2007) 
to 0,9/1,000 live births (2008-2017). The case-fatality rate of all patients with EOS was 
unchanged at 7%. The proportion of neonates with gestational age <28 rose during the study 
period but the incidence of GNB- sepsis remained unchanged (128). There are no present 
studies of incidence and mortality of GNB-LOS in Sweden.  
The neonatal mortality in Ecuador has increased from 5.3 to 6.0/1,000 live born between the 
years 2010-2018. The total under five-mortality has decreased from 12.6 to 12.2/1,000 born 
during the same years (129) There are no available data on mortality due to neonatal sepsis in 
Ecuador.  
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2.7.3 Causative pathogens of early and late onset sepsis 
The distribution of pathogens causing neonatal sepsis varies between regions and over time. 
It varies even within hospitals due to the demographic characteristics of the patients, the 
microflora colonization of the environment and the local antibiotic stewardship (130). 
Hospital-based studies suggest that EC, Streptococcus agalactiae (group B streptococci, 
GBS), Staphylococcus aureus (SA) and KP are the most common pathogens causing neonatal 
sepsis globally. Etiological data for neonatal sepsis is challenging to collect and there are few 
community based etiological studies from LICs.  
EOS is often caused by GBS, EC and Listeria monocytogenes while LOS is more often 
associated with SA, coagulase-negative staphylococci (CoNS), and Gram-negative bacilli. In 
the Gram-negative bacilli group, EC and KP, are the most clinically relevant species but 
CoNS is the most common pathogen group causing LOS in the extremely preterm born 
neonates (121, 131). In figure 6, the most common causative pathogens of neonatal LOS are 
presented. The data is from a review article of 11 LOS- studies and presents the incidence by 
geographical areas.  
 
Figure 6: The most common causative pathogens of neonatal LOS. Copyright: Dong et al, 2014. With 
permission to publish from Arch Dis Child Fetal Neonatal ED.  
 
CoNS accounts for approximately 53-78 % of LOS in HICs and 36-47% in LICs. Neonatal 
sepsis caused by anaerobic bacteria is uncommon. In the rare cases this occurs, the risk 
factors for be affected by anaerobic bacteria infection have been shown to be necrotizing 
enterocolitis, multiple abnormalities, and repeated steroid use (132).  
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2.7.4 Diagnostic methods and their challenges 
The basics of bacterial diagnostics are culture approaches and the gold standard of the sepsis 
diagnosis is the blood culture. These laboratory investigations are time-consuming processes 
and generally takes around 48 hours (106, 133). Insufficient sample volumes, low-density 
bacteremia and antibiotic treatment prior to culture can reduce the performance of the culture 
and post mortem cultures have shown to be falsely sterile (134, 135). One milliliter (1 mL) is 
the recommended minimum volume for a blood culture. When the volume is sufficient, this 
method has shown to have a good sensitivity even when the level of bacteremia is as low as 
1-4 colony forming units (CFU) per mL.  
The sensitivity decreases by 10-40% when sampling 0.5 mL of blood (136). PCR techniques 
are not widely used as a diagnostic tool in neonatal sepsis, but it has been suggested that a 
positive 16S PCR can be used to support initiation of antibiotic treatment in culture-negative 
suspected neonatal sepsis (137). Figure 7 illustrates the existing and desired workflow in 
diagnosing neonatal sepsis.  
 
 
Figure 7. Existing and desired workflow in diagnosing neonatal sepsis. 
 
Positive predictive value and sensitivity of biomarkers like C-reactive protein (CRP), Pro-
calcitonin (PCT) and interleukins are at the onset of EOS suboptimal. This is due to perinatal 
non-infectious conditions such as meconium aspiration, complicated labor and 
intraventricular hemorrhage, that gives a rise in CRP and PCT (138). These methods are, 
nevertheless, used as diagnostic tools for sepsis in neonates whereas CRP is the most studied 
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biomarker. CRP rises physiologically in full term healthy neonates during the first 48 first 
hours of life.  
After a vaginal delivery, CRP in a healthy term infant can reach CRP values between 40-50 
mg/L (139, 140). PCT and CRP levels are affected by gestational age and preterm neonates 
are not responding with as high CRP and PCT levels, as full term neonates do (141, 142). 
CRP and PCT does not pass the placenta and is therefore not affected by maternal fever in 
labour(143). PCT, CRP and total blood count (CBC) is alone inaccurate to define neonatal 
sepsis unless the blood culture is positive (110). 
 
2.6.5 Antimicrobial management of confirmed EOS/LOS and suspected EOS/LOS 
Antibiotics are the most commonly used drugs in neonates worldwide. The antibiotic 
treatment is can be given either divided into when pathogens are known, or when suspected 
(empirical treatment).  
Due to many risk factors for neonatal sepsis among preterm born infants, many of them are 
exposed to empirical or prophylactic antimicrobial treatment. The regimen, including 
duration of prophylactic antibiotic treatment, probably varies between different NICUs and 
even between neonatologists. The choice of empirical therapy should be decided by the 
antibiotic resistance susceptibility pattern of the bacteria often found in the specific NICU or 
in the community.   
In international sepsis networks, the empirical treatment of culture confirmed EOS, is 
suggested to be ampicillin and an aminoglycoside. A cephalosporin (cefotaxime) should be 
used if meningitis is suspected. If no pathogen is isolated, the consideration should be given 
to ending. For EOS, 10 days of treatment is suggested and for GBS or uncomplicated 
meningitis the treatment should last 14 days. If the infection is complicated, the treatment 
period can be extended up to 21-28 days. The empirical treatment for LOS is vancomycin and 
an aminoglycoside (106).  
To reduce the selective pressure from the cephalosporin usage, a penicillin and 
aminoglycoside combination is recommended. When GNB- sepsis is proven or strongly 
suspected a third-generation cephalosporin should replace the penicillin. Piperzillin-
tazobactam combination covers the Gram-negative bacteria better than the penicillin-
aminoglycosides combination with lower risk than cephalosporins of driving resistance, but is 
not commonly used in neonates (144). 
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Nowadays in Sweden, the recommended empiric treatment for EOS is benzylpenicillin in 
combination with an aminoglycoside. For LOS with mild clinical symptoms of sepsis the 
recommended empiric treatment is isoxazolylpenicillin and an aminoglycoside, and for 
severe clinical symptoms, the empiric treatment is cefotaxime plus an aminoglycoside. 
Vancomycin is chosen when resistant CoNS is suspected. 
 
2.7.5 Suspected sepsis 
Neonates with culture-negative sepsis but suspected contribute to a high antibiotic 
consumption in NICUs. Studies conducted in HICs report a significant higher use of 
antibiotics in suspected sepsis than culture-proven cases (109, 145, 146). The clinical 
symptoms and the pathophysiological response to bacterial infection differ in term and pre-
term neonates due to age-dependent maturity.  
If the antibiotic treatment is continued longer than 36 h despite negative blood-cultures in 
EOS, the National Institute for Health and Care Excellence (NICE) guidelines from the 
United Kingdom, suggest that the neonate should be reviewed, for continuation of treatment 
every 24 h (147). There are limited data on the difference in outcome between suspected 
sepsis and confirmed sepsis but effective interventions to reduce antibiotic consumption have 
been successful (145). 
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2.8 COLONIZATION AND INVASIVE INFECTION OF EPE 
Most studies on EPE-colonization are conducted in adults. A high rate of EPE-acquisition 
have been showed in European travellers that returns from Asia (148), sub-Saharan Africa 
and Latin America (149). The duration of the EPE-colonization is relatively short, since in 
healthy persons, the EPE are most commonly outcompeted by other species in the intestinal 
microbiome (149). Contrarily, when the pathogen has colonized or infected patients in a 
hospital setting, the abundance of ESBL-KP declines over time when the patients have 
reached a healthy state outside of the hospital setting (30).  
Specific virulence factors of the bacterial strain play a role for EPE-colonization and the 
colonization rate has been presented as (43%) in adult patients 12 months after the ESBL-EC 
infection (149, 150). A hypothesis on the dynamics of intestinal EPE-colonization is seen in 
figure 8.  
 
 
Figure 8: A hypothesis on the dynamics of EPE-colonization.  
 
2.8.1 EPE in neonatal intensive care units 
EPE-colonization in neonates is clinically important since colonization of EPE is a critical 
step in the pathogenesis of invasive infections. It has been shown that EPE-colonization is 
associated with subsequent invasive infections caused by the same strain of colonized 
neonates (151-153). The progression to infection is not only reliant on the 
immunocompetence in the neonate, but also on the genes the bacteria possess (154). 
In a Swedish study from a NICU in Lund 2013, the prevalence of the EPE-colonization was 
1.77% in a non-outbreak situation. This was considered low in a global perspective. Although 
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there is relatively low level of spread of antimicrobial resistant bacterial strains in Swedish 
NICUs, there have been a number of outbreaks of intestinal EPE-colonization in recent years.  
A number of factors have been associated with neonatal intestinal EPE-colonization, such as 
low birth weight, low gestational age, long hospital stay, early-onset pneumonia, CS, 
maternal to neonatal transmission and prior treatment with antibiotics (155, 156). The 
maternal-neonatal transmission of EPE is high, in both LIC and HIC, and maternal 
colonization is proposed to be the most important risk factor for intestinal EPE-colonization 
in neonates. Vertical transmission of EPE from mother’s breast milk to the neonate has been 
shown during an outbreak (157). Treatment of intestinal EPE-colonization is not 
recommended (155, 158, 159). 
Carbapenems are the drugs of choice in neonatal EPE-infections and are recommended to be 
used as a monotherapy. The use of older antimicrobial agents, such as colistin, has been 
reintroduced because of the emergence of multi-drug resistant Gram-negative bacilli. This 
drug has earlier been associated with adverse effects such as nephrotoxicity. Colistin is 
effective and reasonably safe for treatment in EPE-sepsis in preterm infants, but unfortunately 
the colistin resistance is reported to emerge as well (160, 161).  
The experience of using fosfomycin in neonates is low and this treatment was for a long time 
considered as the last option to treat carbapenem resistant EPE(162). In later years, new 
antibiotics such as, ceftazidime-avibactam, ceftozolane/tazobactam and meropenem, have 
been introduced. Limited data exist on use in children and especially neonates (163, 164).  
 
2.8.2 Outbreaks of EPE in NICUs 
NICU settings are particularly vulnerable due to high antibiotic use, immunocompromised 
patients and high transmission of bacteria between patients or between patients and staff and 
parents. A systematic review of 276 NICUs and 453 other ICUs showed that 
Enterobacteriaceae significantly more often caused outbreaks in NICU than in other ICUs 
(165).  
Some specific clones of resistant EPE, i.e. E. coli ST131 have reached pandemic spread and 
carbapenem-resistant producing Enterobacteriaceae (CPE) have been detected worldwide in 
recent years (166, 167). 
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The spread of EPE-bacteria in NICUs may also occur in non-outbreak periods and may be the 
result of diffuse cross-transmission related to poor infection control procedures (168).  
In Scandinavia, the first described EPE-outbreak at a NICU was an outbreak of CTX-M-15 
KP in 2008-2009 in Norway. This was at the same time that a EPE-outbreak occurred at two 
NICUs at Karolinska in Stockholm. The situation regarding neonatal EPE-colonization or 
EPE-outbreaks in NICUs in Ecuador was unknown before our study. Reports from other 
parts of the region have shown a high frequency of ESBL-producing bacteria as well as 
limited resources for infection control and antibiotic resistance surveillance (156, 169, 170).  
However, in contexts where the resistant bacteria have reached endemic levels, the dynamics 
of transmission seem to depend more on environmental factors in the NICUs. The first 
blaNDM-1 -producing KP in a NICU in South America was found in Colombia in 2013 (171). 
LICs and LMICs face large challenges in preventing MDR-outbreaks e.g overcrowded and 
under-staffed nurseries, lack of essential equipment (soap, clean water, sterilizers), lack of 
aseptic techniques and lack of limited possibilities to follow existing guidelines to optimize 
infection control (168). In an analysis of the global strategies to tackle antimicrobial 
resistance it seems that LIC and LMIC more difficulties in following the guidelines published 
by the Centers for Disease Control and Prevention and WHO (172).  
In Sweden, successful action to contain ABR has included monitoring antibiotic use, active 
surveillance of resistance, educational activities and an achieved commitment at all levels of 
health and medical care (173).  
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3 AIMS 
The overall aim of this Thesis is to improve health of infants and the older children by 
presenting how and to what extent ESBL-producing Enterobacteriaceae (EPE) colonize and 
infect newborn infants in an era of emerging antibiotic resistance.  
The specific aims are: 
 
Study I 
- to highlight and determine the extent of the problem of ABR by showing the 
proportion of intestinal EPE- colonization among neonates and identifying the 
risk factors of aquistition of EPE in a tertiary NICU in Ecuador.  
Study II and III 
- to characterize Klebsiella pneumoniae isolates in an outbreak of ESBL-
producing Enterobacteriaceae in a NICU in Sweden. 
-  to determine the duration of colonization of EPE after discharge.  
- to investigate possible horizontal resistance gene transfer between bacterial 
species and between neonates during the outbreak, by using an optical DNA 
mapping technique.  
- to highlight the usefulness of optical DNA mapping for revealing details about 
resistance carrying plasmids in an EPE-outbreak in a NICU-setting. 
Study IV  
- to determine the incidence, mortality and bacterial characteristics of neonatal 
sepsis caused by Gram-negative bacilli (GNB) sepsis in Stockholm County 
during 2006-2016. 
-  to present to show the extent to which antibiotic resistant Gram-negative strains 
have been invasive in this patient group. 
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4 METHODS 
4.1 ETHICS 
 
The Swedish Ethical Review Authority approved all studies in this thesis.  
In study I, written information about the study was given to the parents in Spanish and verbal 
consent was obtained and documented in the patient´s medical record. The Regional Ethical 
Committee of Cuenca University, Ecuador approved the part of the study that was conducted 
in Hospital Vicente Corral Moscoso. In study II and III, written informed consent was 
obtained from all parents of the included neonates.  
Study IV is a retrospective register study and spans a large time interval, which is why it was 
not considered reasonable or possible to obtain approval from each individual that 
participated in the study. Other similar surveys have shown that parents generally have great 
satisfaction in being able to contribute to current research issues. No identifiable data can be 
linked to any study subject.  
 
4.2 PATIENTS AND SETTINGS 
 
Table 2. Characteristics of each study population and setting in the four different papers 
Paper Inclusion cr iter ia Setting
 
All admitted neonates>24 h of age
All neonates colonized with 
ESBL-KP at discharge from NICU 
after EPE-outbreak
All neonates with culture-confirmed 
Gram-negative sepsis between 
January 2006-December 2016.
One third level NICU, 24-beds, 400 admissions/year
Hospital Vicente Corral Moscoso, Ecuador
Patient-nurse ratio 7:1
Shortest space between incubators 75 cm
Two third level NICUs, 46-beds, 1,000 admissions/year
Karolinska University Hospital, site Solna and 
HuddingePatient-nurse ratio 3:1
Four 2-3 level NICUs, 80-beds, 2,900 admissions/year
Karolinska University Hospital, site Solna, Huddinge, Danderyd and 
Sach´s Children hospital, Stockholm Patient-nurse ratio 3:1
I
IV
II-III
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4.3 STUDY DESIGN 
Study I, was a prospective cohort surveillance study of EPE-colonization at a third level 
NICU at the Hospital Vicente Corral Moscoso, Cuenca, Ecuador. In study II-III, we 
followed 14 neonates, colonized with EPE after a 5-months long outbreak, prospectively for 
five years after their discharge from two NICUs in Stockholm. The follow-up period was 
every second month for two years after discharge and the children were cultured again three 
times during 6 successive weeks at age five years. Study IV, a matched cohort study, based 
on registry data and medical records, was undertaken where all neonates with GNB-sepsis at 
Stockholm´s four NICUs between January 2006 and December 2016 were included. 
 
4.4 DATA COLLECTION 
4.4.1 Study I  
In study I, data on patient characteristics of each neonate was retrieved from the medical 
records in Hospital Vicente Corral Moscoso, Cuenca, Ecuador. Stool samples were collected 
from admitted neonates every two weeks during a three-month period. We collected data on 
risk factors for vertical transmission of EPE from the mother and as well for acquired 
colonization during NICU stay.  
4.4.2 Study II and III  
In study II-III, we collected data on patient characteristics from the electronic medical record 
system Take Care. We collected stool samples from hospitalized neonates every two weeks 
until discharge, thereafter every two months until two years of age. A long-term follow-up 
was conducted. This follow-up consisted of three subsequent sample collections, every other 
week, during a six-week period five years after discharge from the NICU. After discharge, 
the caregivers filled in a form about antibiotic therapy, international travel, hospital visits and 
the use of probiotics.  
4.4.3 Study IV 
All data for study IV was collected from the Swedish Neonatal Quality Register (SNQ)(174), 
the Medical Birth Register (MBR) and from the electronic medical record systems Take Care 
and Clinisoft. To identify the patients to be included we used the ICD-10 codes for bacterial 
sepsis We defined sepsis as: a positive blood-culture, at least two clinical signs (fatigue, 
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respiratory instability, temperature instability, poor feeding, vomiting, cyanosis) and 
antibiotic therapy for at least five days.  
All patients with GNB-sepsis were matched with two groups of controls. The three groups 
were matched by gestational age, the close birth date (the nearest birth date as the case) and 
born at the same hospital. The first control group were matched with a 1:1 ratio and consisted 
of patients with suspected sepsis with clinical symptoms, a negative blood culture and 
subsequent antibiotic therapy for at least 5 days.  
The second control group consisted of uninfected controls that were alive at 72 hours of age. 
The uninfected controls were matched with a ratio of 1:2.6 (74 LOS cases:196 uninfected 
controls). The uneven We excluded the cases with Gram-positive sepsis in the regression 
analysis. The age at infection of the case became the index age for the controls, in the 
mortality analysis. 
 
4.5 SELECTION OF BACTERIA 
All EPE was screened for in study (I), and we found and analyzed KP-ESBL and EC-ESBL. 
In study II-III, the main focus was on ESBL-KP but ESBL-EC isolates were as well 
thoroughly studied. In study (IV), all Gram-negative bacteria were analyzed with 
susceptibility testing.  
We retrieved 33/107 Gram-negative strains from the study period for further molecular 
characterization. These strains were collected in the calendar year of 2010 and from 2013-
2016. Other strains were only frozen for 5 years and thus not available.  
The Gram-negative bacteria study (IV) refers to are the following species: EC, KP, K. 
oxytoca (KO), K. aerogenes (KA), Enterobacter cloacae (ECL), Citrobacter koseri (CK), 
Serratia marcescens (SM), Proteus mirabilis, Pseudomonas aeruginosa (PA), Acinetobacter 
baumannii (AB) and Haemophilus influenzae (HI).  
The Gram-positive organisms that were considered as pathogens were Streptococcus 
agalactiae (group B streptococci; GBS), SA, CoNS, Streptococcus pyogenes (group A 
streptococci; GAS), Enterococcus faecalis and Streptococcus pneumoniae. The following 
pathogens were considered to be likely contaminants: Neisseria species, Rothia mucilaginosa, 
viridans group streptococci and B. cereus (175). Blood cultures with contaminants are not 
presented herein.  
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4.6 ESBL-SCREENING, SPECIES IDENTIFICATION AND SUSCEPTIBILITY 
TESTING 
In Ecuador (I), the first screening for ESBL-producing isolates was done on MacConkey agar 
containing cefotaxime and ceftazidime 1 mg/L. The phenotyping and the ESBL-confirmation 
were performed by the disk diffusion method on Müller Hinton agar plates with ceftazidime 
and cefotaxime +/- clavulanic acid (Beckton Dickinson, BLL) at two different laboratories; 
the laboratory at the Medical University of Cuenca and the PAHO-certified microbiology 
laboratory of SOLCA in Cuenca. The ESBL-screening in study II-III was performed on 
ChromID agar (bioMérieux).  
Species identification and susceptibility testing, of all ESBL-isolates in this thesis was 
performed at the Department of Clinical Microbiology at Karolinska University Hospital, 
Stockholm. The methods used were Vitek2 (bioMérieux) and disc diffusion (Oxoid, 
Basingstoke, UK). and interpreted according to the guidelines using EUCAST breakpoints 
(study I- IV)(176).  
Antibiotic susceptibility testing was performed by the disk diffusion method and interpreted 
according to the guidelines of the Swedish Reference Group of Antibiotics before 2011 (I), 
and between 2011-2016 (II-IV) by guidelines from the European Committee on 
Antimicrobial Susceptibility Testing (www.eucast.org).  
In study II, we determined the relative dominance of the ESBL-KP and ESBL-EC at each 
sampling occasion. We used a culture approach on MacConkey agar to perform this and 
considered the dominance as high if at least one of the two most dominating colonies was the 
EPE-strain.  
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4.7 VIRULENCE AND RESISTANCE GENE DETECTION 
The molecular identification of blaCTX-M and the assignment to distinct CTX-M 
phylogroups was performed by a probe-based PCR-assay (study I-IV) (177). 
In paper I, the microbial typing system of DiversiLab (DL) was used in order to show 
relatedness between isolates (bioMérieux, Marcy l´Etoile, France) (178). Multi-locus 
sequence typing (MLST) was performed according to the guidelines available on the Pasteur 
Institute MLST website, on selected CTX-M producing KP-isolates. 
In order to present genetic information regarding the antibiotic resistance genes and the 
phylogenetic relation between the isolates, we performed WGS at the Science for Life 
Laboratory (SciLife, Solna, Sweden) (study II-IV), multi-locus sequence typing (MLST) 
(study II-IV), core-genome MLST (cgMLST) (study II-III) and pulse field gel 
electrophoresis (PFGE) (study II-III).  
In study III, complete genomic DNA (chromosomal DNA and plasmids) was isolated used 
to extract DNA. The methods to perform long read sequencing of the plasmid is further 
presented in the method part of paper III. We used the resources ResFinder, PlasmidFinder, 
and VirulenceFinder to detect plasmid replicons, resistance genes and virulence genes, by 
submitting de novo assembled contigs for each bacterial isolate to these online resources 
found at the Center for Genomic Epidemiology, DTU, Denmark (179-181). 
The isolates that were closely related in the MLST analysis (study IV) were further analyzed 
with single nucleotide polymorphism (SNP) analysis in CLC Workbench (182).  
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4.8 OPTICAL MAPPING IN PLASMIDS 
In study III, we used optical mapping to get an overview of the plasmid content in all ESBL-
KP samples and some of the ESBL-EC samples. We considered the ESBL-KP outbreak as 
the clinically most important due to KP´s ability to spread in hospital environments.  
All plasmids were extracted from the ESBL-KP and the ESBL-EC strain and separated from 
chromosomal DNA. Netropsin and YOYO in a molar ratio of 100:1 were used to form the 
emission intensity variation along the DNA and obtain the barcode. In order to compare 
plasmid length, a lambda-DNA which has a known number of base pairs (48,502) was 
simultaneously stained together with the plasmids.  
Cas9 and gRNA targeting blaCTX-M group 1 was added to the plasmid solution following a 
previous published protocol (47). The methods used to suppress photo nicking and photo 
bleaching of the DNA molecules are described in the method part of study III. The 
nanochannels used to stretch the plasmids linearly were fabricated, dimensioned and cleaned 
according to previous methods (44, 183). The plasmids were forced into the nanochannels by 
applying pressure with nitrogen gas.  
To image the DNA molecules, an inverted microscope equipped with a 100 x oil immersion 
objective and an EMCCD camera was used. The DNA molecules were imaged for 200 
frames with 100 ms exposure time. The underlying DNA sequence of the plasmid was 
reflected by the barcode and therefore each plasmid given a specific ID. All unique barcodes, 
sizes and numbers of the plasmids were determined in each sample.  
The barcode of the plasmid was compared with long-read PacBio sequencing of the plasmid 
to see if the prediction of the location of blaCTX-M-15 gene was correct by Cas9. 
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4.9 STATISTICAL METHODS 
Table 3, all the statistical methods used in the four studies are summarized. For further details, see the section 
on statistical methods in the specific studies.  
 
 
 
 
 
 
 
 
 
 
  
Compar isons between var iables  Study I Study I I Study I I I Study IV
Dichotomous variables
Pearson´ s X2 test
Fischer´s exact test
Continous variables
Wilcoxon rank-sum
Two sample t-test
Pearson´ s correlation
Logistic regression
Cox-regression
X
X
X
X
X
X
X
Multivariable analysis
X
X
X
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5 RESULTS 
5.1 STUDY 1 
 “High proportion of intestinal colonization with successful epidemic clones of ESBL-
producing Enterobacteriaceae in a neonatal intensive care unit in Ecuador” 
 
We collected 123 EPE isolates from 73 admitted neonates, during the study period. Forty-one 
neonates (56%) were colonized with EPE at some point during the hospital stay. The majority 
of the EPE-strains were ESBL-EC (89%) and the rest were ESBL-KP (11%). No other EPE 
was found. Multiple colonization, meaning colonization with two or more DL-types, was 
found in 27% (11/41) of the neonates. Most neonates patients harbored the bacteria until 
discharge. 
The gestational age of the neonates varied between 29-41 weeks (mean 35.5 w) and their 
birth weight between 500 and 4900 g (mean 1972 g). Of those colonized, 74% (31/41) had a 
positive stool culture already at study entry (the first rectal swab after admission).  
Forty-five infants (62%) received antibiotics during their NICU stay. Gentamicin resistance 
occurred in 98.2% of EC and 100% of KP. Ciprofloxacin resistance occurred in 98.2% of EC 
and 0% of the KP. All EC were susceptible to amikacin, unlike the KP strains which were all 
resistant to this antimicrobial. All strains were susceptible to meropenem and imipenem.  
The results from this study show that a large proportion of the admitted neonates became 
colonized with EPE and that they were resistant to the empirical first- and second-line 
antibiotics for neonatal sepsis. The first line empirical antibiotics were ampicillin and 
gentamycin. Ceftriaxone in combination with cloxacillin was the most common second line 
alternative.  
All but two patients receiving ceftriaxone also received cloxacillin, which is why impossible 
to analyze them separately. Regarding the high level of resistance to ciprofloxacin, normally 
not used in the neonate, we cannot draw any conclusions other than it reflects a general high 
consumption of quinolones within the hospital or/and in society.  
The results of the epidemiological typing divided the ESBL-KP into two clusters and the 
ESBL-EC isolates into two clusters and one singleton. All ESBL-KP and ESBL-EC isolates 
harboured blaCTX-M of phylogroup 1, except for the singleton ESBL-EC isolate that harboured 
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blaCTX-M of phylogroup 9. 
 The different strain types of ESBL-EC and ESBL-KP isolated from various sampling 
occasions can be seen in study I (184). We performed MLST on three representative KP-
isolates of each DL-type (n=7) and could thereafter showe that five (n=5) belonged to the 
ST897 lineage and two (n=2) to the ST855 lineage.  
Characteristics of the infants and risk factors for colonization with ESBL-producing Gram-
negative bacteria during NICU care are summarized in table 4. In the univariate model birth 
weight > 2,500 g, shorter NICU stay, no use of ceftriaxone was significantly associated with 
less ESBL colonization. In a stepwise logistic regression model, a length of NICU stay 
longer than 21 days and enteral feeding with a combination of breastfeeding and formula 
feeding were significantly associated with ESBL colonization.  
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Table 4. Characteristics of the patients and risk factors for colonization with EPE during NICU care in a 
tertiary hospital in Ecuador Note: In the univariate analysis, when more than two categories were represented 
within a factor, each category was compared to all other categories. *Associated with colonization, 
**Associated with less colonization. NS- Not significant. 
 
Character istics No (%) Colonized (n=41)
Not 
colonized
(n=32)
P- Values 
Univar iate model
P-values
Forward step 
logistic regression
Sex  (male) 53.4 23 16 NS
Gestatonal weeks
>36 31 (42.5) 13 18 NS
35-36 20 (27.4) 11 9 NS
32-34 15 (20.5) 11 4 NS
<32 7 (9.6) 6 1 NS
Birth weight
>2,500 15 (20.5) 4 11 0.02**
2,000-2,499 10 (13.7) 5 5 NS
1,500-1,999 33 (45.2) 19 14 NS
<1,500 15 (20.5) 13 2 0.009*
Mode of delivery 
(Ceasarean section) 40 (54.8) 24 16 NS
Length of stay in 
NICU, days
1-10 20 (27.4) 6 14 0.0081**
11-20 22 (30.1) 8 14 0.039**
21-30 15 (20.5) 12 3 0.045* 0.003*
>30 16 (21.9) 15 1 0.0005* 0.001*
Endotracheal tube 20 (27.4) 13 7 NS
Central venous catheter 5 (6.8) 3 2 NS
Parenteral nutrition 21 (28.8) 16 5 0.038*
Breast milk feeding only 28 (38.4) 13 15 NS
Formula feeding only 19 (26.0) 9 10 NS
Both breast milk and 
formula feeding 26 (35.6) 19 7 0.048* 0.006*
Ampicillin/Gentamycin) 28 17 NS
Ceftriaxone, days
0 51 (69.9) 23 28 0.0046**
1-5 5 (6.8) 4 1 NS
6-10 10 (13.7) 7 3 NS
>10 7 (9.9) 7 0 0.016*
Malformations 2 (2.7) 1 1 NS
APGAR at 5 min < 2 (2.7 1 1 NS
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The length of hospitalization was ranged from3 to 61 days (mean 20.6 days). The mean time 
between admission and first surveillance swab was 6.4 days. One limitation of this study is 
the short study period of only three months, but we considered it to be enough to address the 
main question. Other limitations are that we did not screen the mothers for EPE-colonization 
and we did not distinguish between EPE acquisition (acquired during ICU stay) and those 
imported (EPE identified directly at admission). Indeed, risk factors associated with 
importation are different tothose for acquisition.  
 
5.2 STUDY 2 
“Neonatal intestinal colonization with extended spectrum beta-lactamase producing 
Enterobacteriaceae- a 5- year follow up study” 
 
Seventeen neonates became colonized by EPE during the five-month long EPE-outbreak. 
Fourteen out of these 14 survived and were discharged from the NICU. The index case in the 
EPE-outbreak was a neonate with a blood-culture confirmed ESBL-KP.  
Three of the ESBL-KP colonized infants also had invasive infections and died during their 
hospital stay. One infant, extremely preterm born in GA 24 w had clinical sepsis signs at two 
days of age, a perforated intestine when three days old and died on the fourth day after birth. 
A second infant GA 23 w had clinical signs of sepsis when 7 days old, a clinically suspected 
NEC, an ESBL-KP confirmed blood-culture and died 8 days after birth. A third, a full-term 
infant died at two weeks of age, after clinical signs of sepsis and renal failure. The peritoneal 
dialysate and tracheal cultures were positive for ESBL-KP but the blood culture was 
negative. In figure 9, a flowchart on the included neonates is depicted  
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Figure 9: Seventeen children became colonized during the outbreak and 14 of them were included in the study. 
Fecal sampling was conducted every month from discharge until 26 months after discharge. There was no 
sampling between 26 months and 5 years after discharge. Sampling was performed on three occasions during a 
6-week period, 5 years after discharge. 
 
Fourteen neonates colonized with ESBL-KP/EC at discharge, were included in the follow-up 
study. ESBL-KP was seen in 13 patients and ESBL-EC in one patient. One patient in the 
study died due to severe bronchopulmonary dysplasia (BPD) 13 months after discharge. The 
patients were born at different gestational ages and were between 2-95 days old (median 15,5 
days) when they were diagnosed with ESBL-KP/EC colonization. The median length of 
ESBL-KP/EC colonization was 12.5 months (range 5-68 months).  
A co-colonization with ESBL-EC was later seen in 7/13 patients during the follow-up period. 
Among surviving children 5/13 (38%) remained ESBL-KP/EC positive 20 months after 
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discharge. Two of 13 children (15%) remained ESBL-KP positive and 1 of 13 children 
carried an ESBL-EC at 23-26 months after discharge. Notably, only one child had two 
negative cultures before the sampling at 23-26 months of age. The duration of ESBL-KP 
colonization and how many of the patients that were sampled on each occasion can be seen in 
figure 1 in the published paper of study II (185).  
In table 5, characteristics of the fourteen study participants are presented. 
 
Table 5. ESBL-KP/EC colonized children two years after discharge from NICU are marked in bold text. Pat 8 
died 13 months after discharge. Pat 1,2 and 4 were followed 26 months after discharge. 
 
At two years after NICU discharge, seven patients had three or more subsequent negative 
cultures and remained culture negative on the last sampling occasion. Ten children were 
followed-up at five years of age and, at that point, one child was colonized by ESBL-EC.  
The characterization of the K. pneumoniae outbreak strain showed that the resistome and the 
virulome of the KP-ESBL strains were identical. The MLST type was ST101 and carried the 
bla CTX-M-15 gene. Clonal relatedness was shown by PFGE between the initial isolate and the 
last isolate taken after two years after discharge and was thereafter confirmed by cgMLST 
typing.  
  
EPE 
at 2 y
GA 
(w)
BW 
(g)
Bir th 
mode
Antenatal 
AB
First 
intestinal  
EPE 
(age in 
days)
Hospital
days
MV
in total 
(days)
NEC Feed type at NICU
LOS at 
NICU
AB 
in 
NICU
AB 
after 
discharge
Travel  
between 
1-5 y 
after 
discharge
Hospital 
care after 
discharge
Probiotics 
after 
discharge
Morbidity 
after 
discharge
Pat 1 No 25+2 698 VD No 64 101 30 Yes BM,F CoNS 47 No Singapore Yes No ARI, GE
Pat 2 No 25+2 761 VD No 95 101 16 Yes BM,F CoNS 34 No Singapore No No ARI
Pat 3 Yes 24+2 756 CS Yes 30 160 24 No BM CoNS 38 Yes No Yes No UTI , ARI
Pat 4 No 27+0 1011 CS No 15 52 0 No BM CoNS 8 Yes No Yes No ARI
Pat 5 No 32+5 2214 CS Yes 16 16 0 No BM GBS 7 No No No No ARI
Pat 6 Yes 27+1 1080 CS No 11 71 8 No BM CoNS 36 Yes Turkey Yes Yes GE, ARI
Pat 7 No 37+6 2814 VD No 2 38 0 No BM No 16 Yes Finland No No ARI
Pat 8 No 26+6 1054 CS Yes 54 134 19 No BM,F CoNS 17 No No Yes No ARI
Pat 9 No 40+6 3060 VD No 4 45 7 Yes BM No 21 No No No No ARI
Pat 10 No 33+5 1330 CS No 3 24 0 No BM No 5 Yes No No No OM
Pat 11 Yes 31+1 1935 CS No 5 20 0 No BM,F No 0 Yes Albania Yes No GE, OM, ARI
Pat 12 No 34+5 2745 VD No 5 8 0 No BM No 0 No No No Yes ARI
Pat 13 No 38+3 2785 VD No 32 31 0 No BM,F No 0 No No Yes No No
Pat 14 No 29+0 1300 VD No 38 50 1 No BM No 6 No No No No No
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Within the ST101 clone we could detect no allelic differences with cgMLST (694 genes). 
The virulence-associated genes found in were kfu, iutA, mrk, irp1 and irp2. These genes 
encode the synthesis of proteins needed for bacterial iron uptake and transportation (kfu, iutA, 
irp1, irp2) and the attachment to host cells by fimbriae (mrk). The capsule type was K29. The 
antibiotic susceptibility pattern and the resistant genes are presented in table 5. 
 
 
Table 5. Antimicrobial susceptibility and resistance of the blaCTX-M-15 positive index strain (ESBL-KP) in the 
long-term follow up study. 
 
When we studied how the EPE-strain dominated the microbiome we saw that half of the 
children (7/14) had a dominant EPE-strain on at least one occasion during the study period. 
Continuing EPE-colonization was demonstrated in the subsequent culture of these children 
following initial identification.  
Compared to the 2 of 7 children with subsequent positive culture in the group without EPE 
dominance, EPE-dominance is suggested as a predictor for prolonged carriage (p = 0.02). The 
patient questionnaire addressed risk factors for change in diversity of the microbiota but no 
statistical conclusions were drawn due to low patient numbers.  
Drug Susceptibilty Antibiotic class Resistance gene in index strain of ESBL-KP
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A summary of the duration of EPE-carriage, the characteristics of the colonizing EPE-strains 
and the relative dominance of the strain at each sampling occasion during follow-up is shown 
below in figure 10. 
 
Figure 10. Duration of EPE-carriage in neonates after discharge from the NICU. The relative dominance of the 
strain at each sampling occasion during follow up.  
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5.3 STUDY 3 
“Optical DNA mapping combined with Cas9-targeted resistance gene identification for 
rapid tracking of resistance plasmids in a neonatal intensive care unit outbreak” 
 
In study III, we present results from Optical DNA mapping of plasmids from the EPE- 
outbreak at two NICU sites at Karolinska 2008-2009. Seventeen neonates were colonized 
during the outbreak, as mentioned above. At the time of plasmid analysis, 6 years later, one 
isolate was not viable, unfortunately. So, our first set of strains were 16 isolates of the ESBL-
KP-outbreak strain. The follow-up cohort and study period was the same as in study II.  
In figure 11, an overview of the patients and the ESBL- KP/EC isolates that were analyzed 
with OM is presented.  
 
 
Figure 11. This is the same cohort as in study II, but here we show which isolates were analyzed with OM. The 
patient number is listed on the vertical axis. ESBL-KP are presented as blue circles and ESBL-KP as pink 
circles. 
 
When analyzing the KP-outbreak strain, each isolate contained two plasmids. One small 
plasmid with a size of 80 kb and one large with a size of approximately 220 kb. In the main 
ESBL-EC strain we found a 130 kb plasmid. The barcodes from the two plasmids that were 
found in the 16 KP-isolates are shown in figure 12. The position cut by Cas 9 is indicated by 
the grey area and means that the small plasmid is carrying the blaCTX-M gene (53). 
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Figure 12: The barcodes from two plasmids, the small (80 kb) and large (220 kb) plasmid, in the ESBL-KP 
outbreak strain from 16 neonates. The grey area indicates the position cut by Cas9. The small plasmid carried 
the resistance gene. For clarity, all barcodes are shifted vertically. The yellow arrows indicate deletions in pat 
3,5, 8. 
By comparing the barcodes of the small 80 kb plasmid in all patients, we could confirm that 
all these plasmids were identical with a p-value <0.01. The p-values were determined using a 
set of 1000 random barcodes with sizes corresponding to the two compared barcodes, as 
described in detail in reference (43).  
The large plasmids all varied somewhat in size between patient isolates. They were all shown 
to originate from the same plasmid, since they harbored a large region (~160 kb) that was 
identical in all isolates and were therefore related. The variation in size was due to deletions 
in three of the plasmids from the ESBL-KP outbreak. The deletions were seen in patient 3 (5 
kb), patient 5 (55 kb) and patient 8(31 kb).  
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Figure 13 A) This figure shows the plasmid barcode of follow-up samples of the EC samples in patient 3,6 and 
8. B) This illustrates how the barcodes from the outbreak KP-strain (gray lines) and the follow-up strain (black 
lines) match. The samples taken 6,12,21 and 23 months after the first samples show that the same plasmids are 
still present. The names of each isolates are PXKY where P is patient, X is the patient number, Y is the month the 
isolates was collected relative to the initial isolate and K stands for K. pneumoniae. 
In the follow up samples we analyzed ESBL-KP from seven of the children. The barcodes 
from all follow-up KP- plasmids can be seen in figure 3 in paper III (186). The PacBio 
sequencing data also allowed us to investigate the genetic rearrangements found in several of 
the ESBL-KP ST101 isolates.  
The sequencing results excellently confirmed the optical mapping data regarding both 
position and size of the deletions. The deletions seen were most likely an effect of 
transposase activity. Figure 4 in paper III illustrates how the barcodes from optical mapping 
and the theoretical barcodes predicted from the PacBio sequencing, were compared and that 
the overlap is excellent (186).  
In the ESBL-EC strain we found a 130-kb plasmid. The plasmid barcodes of the EC-isolates 
and some of the follow up samples of the ESBL-KP strains are presented in figure 13. PCR 
analysis of the ESBL-EC strain revealed that this isolate also carries a bla CTX-M-group 1 gene, 
but the Cas9 assay did not show that the gene was not present on the 130-kb plasmid. We 
performed PacBio sequencing also on one of these isolates (Patient 3 after 5.5 months), to 
support the optical DNA mapping data. The barcode of this plasmid did perfectly overlap 
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with the theoretical barcode predicted from the sequencing. The resistance gene was located 
on the chromosome of this EC. 
Finally, we investigated whether or not there had been plasmid transfer between KP and EC 
due to conjugation. We compared all plasmid content of all EPE-isolates by optical mapping 
and ODM demonstrated identical 130 kb plasmids in all the ESBL-EC and they did not 
resemble any of the barcodes of the plasmids from the ESBL-KP strain, which indicates that 
the ESBL-EC plasmid had a different origin. We can, with this result, state that there was no 
plasmid transfer between KP and EC in this outbreak.  
ODM can rapidly characterize plasmids directly from fecal samples. After a short cultivation 
step in broth (< 4h), the plasmids can be extracted and typed using ODM and the genetic 
analysis can be completed on the same day that the sample was collected. 
 
5.4 STUDY 4 
“A decade of neonatal sepsis caused by Gram-negative bacilli- a retrospective matched 
cohort study” 
 
During the study period 310,091 infants were born alive at the obstetric departments of the 
delivery units in the Stockholm area. Of these, 31,878 (10.2%) neonates were admitted to the 
neonatal units of Karolinska Danderyd (n=10,418), Karolinska Solna (n=5,828), Karolinska 
Huddinge (n=6,904) and Södersjukhuset (n=8,728). 
A total of 804 admitted infants (table X) had at least one positive blood-culture, which 
corresponds to a total incidence of culture-confirmed neonatal sepsis of 2.6/1,000 live born.  
The incidence of GNB sepsis in neonates in the Stockholm area between the years 2006-2016 
was 0.35 cases per 1,000 live born. Divided into GNB-EOS and GNB-LOS, the incidence 
was 0.11 and 0.24/1,000 live births respectively. GPB-sepsis was 6.3 times more common 
than GNB-sepsis with an incidence of 2.2 per 1,000 live born. Among the infants admitted to 
the neonatal unit, 1,026/31,878 (3.2%) had suspected sepsis (not culture-verified sepsis) with 
a cumulative incidence of 3.3 per 1,000 live born. Described as NICU-admissions, EC-EOS 
was 0.75/1,000 admissions and EC-LOS was 1.4/1,000 admissions. We did comparisons 
between neonates with GNB-sepsis and two other groups of matched controls.  
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Figure 14: Flow chart of all patients included in study IV 
The median gestational age at delivery in patients acquiring GNB-EOS was 34 weeks (IQR 
26-38) and in GNB-LOS 27 weeks (IQR 25-29). The median age at diagnosis was 1 day 
(IQR 0-1) for EOS and 19 days (IQR 11-31) for LOS. Median onset for suspected EOS was 
day 0, day 19 (11-31) for GNB-LOS and day 9 (IQR 4-17) for suspected–LOS. The 
difference between the GNB-LOS and suspected was significant (p<0.001) 
Maternal antibiotics were more commonly given to neonates that developed GNB-EOS as 
well as GNB-LOS compared to the uninfected group. The difference was significant and the 
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proportions were (52% vs 16%) and (49% vs 40%) respectively.  
Birth mode did not differ in the GNB-EOS group, but was in the GNB-LOS group more 
common (42%) than in both suspected-LOS (15%) and uninfected controls (22%). 
The characteristics of all 107 GNB cases (GNB-EOS and GNB-LOS) and the pair-wise 
comparisons with suspected sepsis controls and uninfected controls are seen in table 8. 
The primary outcome in study IV, was to present the in-hospital mortality of neonates with 
GNB-sepsis. We showed that 30 of all 107 neonates with GNB-sepsis died before discharge 
and present it as the case fatality rate (28%). The mortality of GNB-LOS was compared with 
the suspected-LOS and uninfected control groups. The proportion of deaths before discharge 
was 35% (25/74), 17.5% (13/74) and 7.6% (15/196). 
The secondary outcome, the 5-day case fatality rate, was 5/33 (15%) in GNB-EOS and 13/74 
(17.5%) in GNB-LOS. 
The logistic regression showed that the adjusted odds ratio (OR) to die before discharge in the 
GNB-LOS groups was 4.7 compared to the uninfected matched control group, and 2.2 when 
compared to the suspected sepsis group. No difference was seen between GNB-LOS versus 
suspected sepsis or suspected sepsis versus controls 
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Table 8. The characteristics of all 107 GNB cases (EOS and LOS) and pair-wise comparisons with suspected 
sepsis controls and uninfected controls.  
*Comparison between case and suspected sepsis 
** Comparison between case and uninfected control, 
*** Comparison between suspected case and uninfected  control 
Continuous variables are presented with means, SD, medians and interquartile range. Categorical variables are 
presented as proportions and %. BW=birth weight, MV= mechanical ventilation, CPAP= continuous positive 
airway pressure, TPN=total parenteral nutrition, pCVC=peripheral central venous catheter, UVC=umbilical 
venous catheter, UAC= umbilical arterial catheter, BPD= bronchopulmonary dysplasia, ROP= retinopathy of 
the newborn, IVH=intraventricular hemorrhage, NEC= necrotizing enterocolitis 
 
 
GNB-EOS
n=33
Susp-EOS
n=33
Uninfected 
control
n=99
P*
EOS
P**
EOS
P***
EOS
GNB-LOS
n=74
Susp-LOS
n=74
 
Uninfected 
control
n=196
P*
LOS
P**
LOS
P***
LOS
Gest age (w) 34 (26-38) 34 (26-38) 34(26-38) 0.94 0.97 0.91 27 (25-29) 27 (25-29) 27 (25-29) 0.98 0.60 0.58
Gender, male 16 (48) 21 (64) 57 (58) 0.16 0.36 0.42 45 (61) 53 (72) 99 (51) 0.16 0.13 0.002
BW (g) 2,225 (994-2950)
2,013
(686-3500)
2087
(995-3325) 0.88 0.81 0.89
885
(750-1395)
812 
(627-1259)
960 
(747-1315) 0.17 0.69 0.04
Apgar at 5 min <7 13 (39) 5 (15) 26 (26) 0.027 0.16 0.18 23 (31) 29 (39) 63 (32) 0.33 0.83 0.33
Caesarean section 16 (48) 16 (48) 50 (22) 0.90 0.96 0.84 31 (42) 11 (15) 44 (22) <0.001 <0.001 0.17
Prenatal steroids 11 (33) 14 (42) 34 (34) 0.72 0.72 0.40 52 (70) 64 (87) 146 (75) 0.17 0.61 0.034
Antenatal 
antibiotics 17 (52) 11 (33) 16 (16) 0.11 <0.001 0.037 36 (49) 31 (42) 79 (40) 0.048 <0.01 <0.81
Onset sepsis (d) 1 (0-1) 0 (0) No sepsis 0.023 19 (11-31) 9 (4-17) No sepsis <0.001
Days of MV 1 (0-7) 0 (0-6) 0 (0) 0.77 <0.001 0.57 8 (2-24) 9 (2-16) 0 (0-7) 0.43 <0.001 <0.001
Days of CPAP 2 (0-8) 1 (0-4) 3 (0-20) 0.31 0.05 0.24 16 (3-36) 18 (2-38) 6 (1-25) 0.77 0.003 0.03
Days of TPN 8 (2-13) 2 (0-10) 1 (0-8) 0.06 0.001 0.001 22 (11-37) 13 (8-24) 9 (5-14) 0.001 <0.001 <0.001
Days of UAC 1 (0-6) 0 (0-2) 0 (0-4) 0.038 0.046 NA 6 (3-8) 5(0-7) 3(0-6) 0.43 <0.001 0.036
Days of UVC 1 (0-5) 0 (0-1) 0 (0-0) 0.062 0.015 NA 1 (0-4) 2 (0-5) 0 (0-5) 0.40 0.72 0.20
Days of pCVC 0 (0-9) 0 (0-9) 0 (0-0) 0.39 <0.001 0.55 15(8-28) 7 (1-20) 2 (0-8) 0.009 <0.001 <0.001
BPD discharge 4 (12) 6 (18) 13 (13) 0.64 0.67 0.78 32 (43) 35 (47) 64 (33) 0.48 0.12 0.083
ROP 1-2 
discharge 4 (12) 6 (18) 2 (2) 0.48 0.004 0.059 9 (12) 20 (27) 26 (13) 0.11 0.99 0.017
ROP 3-4 
discharge 4 (12) 0 (0) 1(1) 0.095 0.01 0.85 10 (14) 4 (5) 9 (5) 0.18 0.019 0.83
IVH 1-2 
discharge 7 (21) 4 (12) 5 (5) 0.32 0.005 0.059 16 (22) 14 (19) 19 (10) 0.55 0.008 0.039
IVH 3-4 
discharge 5 (15) 3 (9) 2(2) 0.48 0.004 0.059 6 (8) 6 (8) 11 (6) 0.60 0.20 0.45
All NEC NA NA NA NA NA NA 27 (36) 15 (20) 5 (3) 0.09 0.059 0.39
Surgical NEC NA NA NA 11 (15) 5 (7) 0 (0) 0.11 0.003 0.78
Mortality before 
discharge NA NA NA 25(34) 12 (16) 33 (17) 0.04 <0.001 0.008
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From the survival analysis, the cumulative survival rate of GNB-LOS and the matched 
controls was presented as Kaplan-Meier curves of 5- and 30-days survival (figure 15). The 
adjusted cox-regression model show that the hazard ratio of dying 5 days after GNB-onset 
was 4.3 (p=0.005) compared to uninfected controls and in GNB-LOS versus suspected LOS 
the HR was 2.8, but not significant (p=0.08). 
 
 
Figure 15. The cumulative survival rate after GNB-LOS onset (index day) in Kaplan-Meier of GNB-LOS.  
 
EC was the most common Gram-negative pathogen causing GNB-sepsis in both GNB-EOS 
and GNB-LOS, followed by Klebsiella spp and Enterobacter spp. The Enterobacter spp 
showed the highest mortality due to a specific pathogen. All culture-confirmed pathogens and 
the proportions of death due to specific GNB are shown in table 9. The Gram-positive 
pathogens predominated with 691/804 (86%) vs Gram-negative 113/804 (14%). 
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Table 9: A total of 804 episodes of neonatal sepsis was confirmed by blood-culture. Left: All confirmed Gram-
negative pathogens and the case fatality by pathogen is here presented. a Due to missing data from four neonates 
and two apathogenic Neisseria, 107 of 113 confirmed Gram-negative pathogens is shown here. Right: Here all 
confirmed Gram-positive pathogens during the study period are presented. b Other includes S. pneumoniae, B. 
cereus, S. pyogenes and S. salivarius. 
 
We retrieved only 33 of the 107 Gram-negative strains from the study period for further 
characterization. This was due to the fact that the strains were only kept for 5 years in the 
freezers of the microbiology laboratory. These strains were collected in the calendar year of 
2010 and from 2013-2016. In these 33 isolates, we performed molecular and genetic 
characterization.  
In the EC group, we found that three patients had the same sequence type (EC ST95) and 
two patients had EC ST357 and therefore SNP-analysis was performed on these isolates. 
They were not correlated in time and NICU-site. No genetic relation was found in the SNP-
analysis. A high level of genetic similarity was seen in a group of S. marcescens infecting 
four patients closely related in time and NICU-site. The S. marcescens strain differed with 
1-3 SNPs and was then confirmed as a small outbreak. Other from this, the data from 
MLST showed a high diversity of STs in the infecting strains E. cloacae (n=4), K. 
pneumoniae (n=4) and E. coli (n=12).  
  
Confirmed Gram-negative pathogens No of GNB-sepsis 
per pathogen
No of GNB-EOS
per pathogen 
EOS 5 days case 
fatality rate  per 
pathogen (%)
EOS mortality 
before discharge
per pathogen
 (%)
No of GNB-LOS
per pathogen
LOS 5 days case 
fatality rate  per 
pathogen (%)
LOS  mortality 
before discharge
per pathogen
 (%)
Escherichia coli
Klebsiella species
Enterobacter species
Serratia marcescens
Acinetobacter baumannii
Pseudomonas aeruginosa
Hemofilus influenzae
Citrobacter koserii
47 2/24 (8.3)24 3/24 (12.5) 23 2/23 (9) 7/23 (30)
24 5 1/5 (20) 1/5 (20) 19
15
10
3
3
1
0
3/19 (15.7)
5/15 (33.3)
2/10 (20)
0
0
-
1/1 (100)
5/19 (26.3)
7/15 (46.7)
4/10 (40)
0
1/3 (33)
-
1/1 (100)
0
-
-
1
0
-
0
-
-
1 (100)
0 (0)
-
1
0
0
1
2
01
16
10
3
4
2
Totala 107 33 5/33 (15%) 5/33 (15%) 74 13/74 (18%) 25/74 (34 %) Total 
Confirmed Gram-positive pathogens Numbers of neonatal sepsis episodes with  casued by 
this pathogen
691
412
149
85
12
21
      Coagulase-negative Staphylococcus
      Staphylococcus aureus
      Group B streptococcus
12
      Enterococcus species
      Alfa-streptococcus
      Otherb
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6 DISCUSSION 
Neonatal sepsis is the leading cause of mortality in the newborn. The main challenge of ABR 
in NICUs has been the Gram-negative bacterial species, where GNB-sepsis is associated with 
higher mortality compared to GPB-sepsis. The NICU is an environment with high antibiotic 
use. Antibiotics are essential for treating life-threatening infections, but antibiotic exposure 
induces unwanted early disturbances in the neonatal microbiota (100, 101). As described, 
dysbiosis of the neonatal gut microbiome has multifactorial causes and the early colonization 
of EPE is a risk factor for subsequent invasive infection (93, 97, 99, 100). A complication in 
studies regarding neonates and ABR is the difficulty of conducting clinical trials for rare 
resistant infections in neonates. The duration of EPE-colonization and the characteristics of 
different EPE bacteria, have in terms of virulence and resistance factors, great clinical 
importance as well as understanding the dynamics of an EPE-outbreak. Therefore, rapid and 
reliable methods for diagnostics and efficient treatment are important when caring for the 
septic neonate.  
Herein, discussion points regarding colonization and infection of Gram-negative bacteria in 
neonates, with focus on ABR, are presented. 
 
6.1 How did this thesis contribute to the knowledge of EPE-outbreaks in NICU setting 
in Sweden? 
There is an increasing prevalence of nosocomial outbreaks caused by EPE in NICUs 
worldwide, but to our knowledge not yet in Sweden. A small number of EPE-outbreaks 
occurede in Swedish NICUs during the period 2006-2009. The National Board for Health and 
Welfare did thereafter recommend screening programs, but sporadic small EPE-outbreaks 
still occur (187).  
Spread of EPE-bacteria in neonatal care may also occur in non-outbreak periods and depends 
on the characteristics of the strain and the cross transmission between neonates by health care 
personnel in the NICU. Cross transmission is often related to poor infection control 
procedures. Hygiene precautions are the key to infection control in all settings. Local 
surveillance is crucial to prevent and control EPE-outbreaks in neonatal ICUs. 
In two studies (II-III), we identified and characterized the EPE-strains that caused a four 
months long outbreak in two of the NICUs in Stockholm. The EPE-outbreak affected 17 
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neonates . We can state that three of these children also had invasive infection with the same 
ESBL-KP strain and died before discharge. We characterized this highly resistant ESBL-KP 
strain in terms of virulence and resistance factors. We concluded that the ESBL-KP-strain 
spread to a greater extent than the co-colonizing ESBL-EC strain, that we also found in a 
small number of patients. We showed that infants can carry the same ESBL-KP strain with 
the intact resistance carrying plasmid for up to 26 months. 
 
In addition to the traditional methods of characterizing of the bacterial strains we could 
confirm by the ODM method that the ESBL-KP outbreak strain carried an identical plasmid 
and therefore indicated an outbreak. We show that the ODM method can become an 
important tool in surveillance of resistant bacteria in a NICU setting. 
Studies show that low-risk interventions such as screening of intestinal EPE in neonates, 
enhanced control measures in the NICU, such as continuous long term surveillance with 
cohorting are associated with a decrease of ESBL-KP acquisition within the NICU (188, 
189). 
 
6.2 What are the risk factors for EPE-carriage in newborns? 
We showed that the main risk factors for EPE-colonization a tertiary NICU in Ecuador were 
length of stay in hospital care settings and mixed feeding with breastmilk and formula (I). 
That a combination of formula and breast milk, but not exclusive formula feeding, was a risk 
factor is interesting and were at the time of our study (I), not in line with previous reports.  
Nutrition has been shown to affect abundance of EPE. Human milk has been demonstrated to 
be a protective factor to reduce colonization and infection with resistant Enterobacteriaceae 
in preterm infants and formula milk made of cow milk is associated with a higher abundance 
of the same (77, 190). Mixed feeding has lately been shown to be a risk factor for viral 
infections such as HIV in infants, probably due to increased inflammation in the gut mucosa 
(191). The finding is interesting but repeated studies are needed before any conclusions can 
be drawn.  
The use of cephalosporins, parenteral nutrition and a low birth weight differed significantly in 
the univariate comparisons of EPE-colonized and non-colonized admitted neonates (I). 
Unfortunately, the groups were not matched by gestational age but the association is 
interesting since they all have been shown earlier to be risk factors for EPE-colonization and 
as well to be factors that can modify the diversity of the neonatal gut microbiome (12, 77, 91, 
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124). Vertical transmission from the mother has been shown repeatedly as the most common 
mode of acquisition for EPE colonization in the neonate (155, 192, 193). In our studies (I-II) 
we did not have the possibility to screen the mothers for intestinal EPE. Other limitations of 
study (I) is the small number of study participants and the short period of observation.  
 
6.3 How long do children carry the EPE bacteria after being colonized in the newborn 
period? 
The length of EPE colonization in adults is associated with the virulence and resistance of the 
strain and the EPE-colonization have been shown to persist for at least 12 months (148, 150). 
When neonates are EPE-colonized in the NICU, the absolute majority remain colonized 
during hospital stay (I, II).  
To answer the question of duration of EPE-colonization we need to know the abundance of 
the resistant bacteria has in the intestine. The EPE-abundance depends on the existing 
commensal bacteria that can balance the resistant strains. As stated before, the dysbiosis in 
the NICU-cared neonatal microbiota is multi-factorial and associated with gestational age, 
birth mode, feeding type and antibiotic treatment. The development of bacterial load and 
neonatal microbiota follows a pattern that depends on both the gestational age and the 
postnatal age when colonized and early gut colonization influences the composition of the 
later microbiota (10, 72, 194). That is why the question of duration of colonization is not easy 
to answer since we need to take that in account together with the virulence factors in the 
colonizing strain. Since we did not characterize the entire intestinal microbiome in each child, 
we cannot present possible explanations for why each child at each sampling moment had a 
dominating EPE-strain.  
The study (II) included 14 patients, which leaves us with sparse possibilities to draw any 
statistical conclusions of possible risk factors for a long duration of EPE-colonization. It is 
likely that the long-term hospitalized neonates that have acquired an epidemic clone in the 
NICU, at early postnatal age is more likely to remain colonized for a longer period than a 
healthy newborn infant that becomes a carrier of a community-acquired EPE-strain. When 
planning study (II) there was a sparse knowledge on whether acquired EPE-colonization 
could persist longer than two years. We describe the median carriage length with ESBL-KP 
as one year after discharge, which is similar to a recent study(195). The longest ESBL-KP 
duration of colonization we can show was 26 months after discharge, which was somewhat 
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longer than previously described. Two years after discharge, there were three children 
colonized with ESBL-KP and ESBL-EC. These were all born by caesarean section and were 
5 (KP)and 11 (KP) and 30 (EC) days old, respectively. 
The child in the long-term follow-up (II), that harboured a dominating strain of ESBL-EC at 
five years after discharge from NICU, had during the two first years of follow up, been co-
colonized with ESBL-KP, ESBL-EC and ESBL-Citrobacter. The child was admitted to the 
paediatric ward due to gastroenteritis and later received a gastrostomy. This was interpreted 
as a re-colonization of ESBL-EC, since EC is a more natural part of the intestinal microbiota 
compared to KP.  
The interpretation of re-colonization was later verified with ODM (III) that confirmed that 
the ESBL-EC strain at 68 months had not acquired any resistance gene by plasmid transfer 
from the outbreak ESBL-KP strain. A hypothesis is that this child had a dysbiotic gut 
microbiome due to other morbidities, antibiotic treatment and hospital stay and therefore was 
susceptible to ESBL-EC acquisition.  
The strengths of study (II) are the five year follow up period and the analyses of relative 
dominance of EPE and duration of EPE-colonization. The study has limitations such as the 
lack of maternal-, breast milk-, and environmental samples and samples from the health care 
workers in order to anlyse the dynamics of the outbreak in more detail. The small number of 
included study participants together with four (n=4) missing at follow-up at age five in 
combination with no culture information between 2 and 5 years after discharge make the 
results less strong than we would have liked. 
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6.4 What impact did a prevalence study of EPE-colonization in neonates have in 
Ecuador? 
At the time when the study (I) was initiated, Ecuador was affected by frequent cases of sepsis 
with a high mortality in many neonatal wards. Ecuador faced great difficulties in treating the 
septic neonates. There was little experience among health professionals of managing ABR, 
and further characterization of the causative agents was not possible. The healthcare system 
was provided with a lot of technical equipment to solve this problem, but few or no 
interventions were made in terms of optimizing the microbial diagnostics and clinical 
approaches. There was at the time, in 2010, no accumulated experience that could contribute 
to a comprehensive and efficient action plan against the spread of ABR bacteria and the high 
sepsis-related mortality in the NICUs of Ecuador. As long as no data exists on colonization or 
resistance patterns, it is less probable that targeted interventions can be initiated.  
Our study, is the first published study of intestinal colonization of EPE in Ecuador and 
therefore the first study on neonatal acquisition of EPE in the country. It showed a high 
prevalence of EPE-colonization, in more than half of the admitted neonates, and the presence 
of a highly successful clone of ESBL-KP known to disseminate carbapenemases was 
presented. We found five epidemic bacterial clusters which can indicate several ongoing 
outbreaks. These results can also be explained by an endemic situation with a high prevalence 
of EPE in the society and the hospital settings. This indicates that the problem with ABR in 
the NICU was deeply rooted, while the awareness among health professionals was low.  
Together with the new knowledge of highly virulent and resistant EPE-strains and the local 
capacity building measures that came out of the collaborative work with the NGO ReAct 
Latin America, the study results and conclusions were presented to the regional health care 
authorities. Medical protocols were changed and the regulations of the hospital were 
strengthened.  
ReAct is short for Action on Antibiotic resistance and is an international network, working 
from five continents, to find global, regional and local solutions that counteract antibiotic 
resistance. React is funded by SIDA and the European head quarter is based at Uppsala 
university. 
The main impact of the study, however, was not on policy-makers but on health care workers, 
students and teachers who, as a result of ReACt´s sharing of the results of this study at local 
and regional meetings, became motivated to initiate other studies and to develop new ideas to 
deal with resistant microbes within local and regional contexts. While the Ministry of Health 
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organized a national meeting with over thousand participants to discuss ABR (196, 197), 
political problems unfortunately intervened, and the activities were interrupted for some 
years. In general, countries that lack specific ABR-policies may provide little guidance on 
how LIC and LMIC can fill in gaps in surveillance policies (1, 172).  
Ecuador started to work with their National Action plan in 2015 and as in many countries, it 
closely reflects the Global Action Plan developed by WHO. A major challenge in these 
settings will be to find key priorities and sustainable measures that are feasible in terms of 
capacity and costs.  
 
6.5 What is the importance of bacterial characterizing of the resistant bacteria?  
Species determination and detecting resistance factors of the bacterial strain are the important 
first steps in order to know how to treat the infection. The epidemiological typing of EPE is 
necessary when characterizing a colonizing or infecting isolate. It is an important tool both in 
routine diagnostics and it provides valuable information about spreading routes in an EPE-
outbreak (114). If a clone of bacteria with a certain successful ST is detected in the NICU, the 
clinician should be prepared for a bacterial strain harder to eradicate, an infection more 
difficult to treat and longer duration of the intestinal colonization of the bacteria. Bacterial 
characterization is also important when it comes to find new sequence type, in the continuous 
evolution of bacteria and their ability to resist antibiotics. 
 
6.6 Are the characterized bacterial strains found in the neonates in these studies local or 
global?  
In Ecuador (I), we found ESBL-EC and ESBL-KP that featured blaCTX-M of phylogroup 1. 
The ESBL-KP belonged to two epidemically successful clones of KP known for rapid 
transmission between patients. The first one, ST855 is a single-locus variant of ST11, and a 
member of the clonal complex CC258, a complex that is known to disseminate 
carbapenemases. The second, ST897 is a single-locus variant of ST14, and hence part of 
CC14. Both CC11 and CC14 are clonal complexes known to rapidly spread carbapenemases. 
These clones had not been shown before in Ecuador but had earlier been detected in Brazil 
(ST 855) and Canada (ST 897). 
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In the two NICUs in Stockholm (II), the bla CTX-M-15 producing ST101 KP-strain that was 
characterized had not been shown before in NICUs in Sweden. However, the strain is 
globally spread and has been observed and presented in studies from southern Europe and 
northern Africa (198-200). 
In the culture confirmed neonatal sepsis cases in Stockholm between 2006-2016 (IV), GPB 
predominated causing 86% of the sepsis vs GNB that caused 14%. The three most common 
organisms causing GPB-sepsis were CoNS, S. aureus and GBS. The most common 
pathogens for GNB-sepsis were EC, KP and Enterobacter spp. The sepsis-causing pathogens 
are similar to the pathogens that were presented in an observational retrospective study about 
EOS in the western part Sweden from 2008-2017 (128).  
We show the presence of EC ST95 in some of the invasive isolates. EC ST95 belongs to a 
globally disseminated clone of EC that is highly associated with neonatal sepsis and 
meningitis. The levels of drug resistance in EC ST95 have been defined as low among 
clinical isolates, but recently a highly virulent EC ST95 lineage has been detected. This 
lineage has, as well, been shown to easily acquire the plasmid-born colistin resistance gene 
(mcr-1). In our material, none of the patients with invasive EC ST95 suffered from 
meningitis. These strains are highly worrisome in clinical practices, and in particularly in 
intensive care units and NICUs where the antibiotic pressure is high (201). 
 
6.7 How can diagnostics with ODM play a role in clinical settings?  
In NICU-settings there is a need for epidemiological tools to detect rapid spread of EPE. 
Traditionally, characterizing plasmids requires several time-consuming techniques. ODM 
can, within a couple of hours, detect and characterize plasmids and as well confirm whether 
or not they harbor the resistance gene. The results can be retrieved in one single experiment. 
In a presumptive outbreak, it is enough to perform long read sequencing on only one isolate 
and thereafter the rest of the plasmids in the isolates can be identified by ODM(186). ODM is 
therefore a suitable method to use in EPE-outbreak situations. 
In study (III), we used the ODM method to determine whether or not the presence of 
resistance genes in different bacterial species was due to plasmid transfer between bacteria in 
the infant and also between neonates. The ODM method showed that there was no 
conjugation of plasmids between bacteria, in contrast to another Swedish NICU where ODM 
at a EPE-outbreak revealed plasmid conjugation (43). ODM confirmed that it was the same 
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strain in the outbreak strain and the multiple follow up strains, since the plasmid, even though 
there had been deletions and insertions in the DNA-sequence, had an identical barcode. By 
ODM we can state that the ESBL-EC in one patient at 68 months was not carrying the same 
plasmid as the KP-ESBL outbreak chain and therefore was therfor a re-colonization. 
By using ODM we confirmed that the location of the CTX-M enzyme of the EC isolates, 
occurring in three of the patients, did not exist in the plasmid and revealed that it was located 
on the chromosome. We also analyzed one additional ESBL-KP-isolate that harbored three 
different plasmids. This strain did not carry the resistance gene in the plasmid, and we could 
therefore conclude that this strain did not belong to the actual outbreak. 
By ODM, we could conclude that this outbreak was plasmid-mediated in the sense that 
resistance genes were carried on a plasmid. Furthermore, we could conclude that the ESBL-
KP outbreak chain was not spread by plasmid transmission within the NICU environment, 
rather it was caused by a classical clonal outbreak. The horizontal spread of the ESBL-KP 
strain was by the health care personnel and underlines the importance of maintaining strict 
infection control measures and guidelines in the NICU setting. ODM has emerged as a 
powerful tool and shown to be a useful method as well in detecting bacterial clonal spread 
(202).  
Promising results from a recent study show that the ODM method is capable of identifying 
bacteria from urine samples directly, without the culturing step, by matching large bacterial 
DNA molecules to a bacterial genome database (203). A method like ODM is an important 
part of the toolbox in the ongoing fight to stop local and global spread of ABR and a step 
forward in targeting the WHO´s Sustainable Development Goals for reducing neonatal 
mortality. 
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6.8 Does the neonatologist need to think differently about neonatal sepsis in low- and 
high-income countries? 
Treatment failure of neonatal sepsis is associated with increased mortality and higher costs, 
which is similar in both settings (12, 124, 125). In LIC settings compared to HIC, where a 
lack of reliable microbiological laboratories and competency regarding infection control is a 
fact, the physician might tend to prolong the duration of antibiotic treatment (168). The 
availability of empirical antibiotic treatment varies highly in LIC and LMIC settings. 
Purchase of over-the-counter antibiotics can lead to inappropriate use of antibiotics (204). 
What is decisive for the clinician is the knowledge of the local burden of ABR, which is a 
practical challenge if there are limited laboratory resources. The clinician needs to think about 
whether or not the neonate has received previous antibiotics, and what type of antibiotic, 
since studies show that antibiotic treatment is a risk factor for subsequent sepsis and that a 
less diverse microbiota is a profound risk factor for neonatal LOS (51). The use of 
cephalosporins in NICU settings significantly increases the incidence of ESBL-producing 
bacteria in neonatal blood cultures (205, 206).  
In study I, it would have been interesting to have gathered data on the association between 
colonization and invasive infection in the LMIC setting. However, the standard of the 
existing microbiological laboratory at the hospital did not allow this and therefore the 
possibilities of this project were restricted. We assume, though, that such a high frequency of 
EPE-carriers indicates that there was a large proportion of invasive cases as well. Since we 
lack data from clinical cultures we cannot comment specifically on the local empirical choice 
of antimicrobial treatment, other than stating that EPE seem to be very common in the NICU 
setting we studied in Ecuador. 
 
6.9 Do we need to study suspected sepsis more? 
The culture confirmed GNB-cases are rare in the Stockholm region, and corresponding to 0.8 
cases per month in the four NICUs (IV). We found that the incidence of culture confirmed 
sepsis with suspected EOS/LOS in admitted neonate was low (ratio of 1:1,3) compared to 
other studies (1:6-16)(109, 145, 207). Most studies on suspected neonatal sepsis in HIC are 
performed on EOS and not suspected LOS. A conclusion from this result might be that we 
have underreported the cases with suspected sepsis in the patients journals and in (SNQ). It 
can also be influenced by the antibiotic stewardship programs set up between 2006-2016 in 
our region.  
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A study on neonatal mortality following LOS has shown that the in-hospital mortality of 
GNB-LOS was 19%. The in-hospital mortality in GBP-LOS caused by CoNS was (8%), 
other GPB (6%) and was similar to in-hospital mortality in patients with a negative blood 
culture (8%). The survival analysis by Cox hazard regression in the same study showed that 
neonates with bacteremia with CoNS (HR 0.92) and other GPB (HR 0.74) had even a lower 
hazards as neonates with negative blood cultures (120). That suggests that there is a slightly 
higher hazard of dying at a specific time point in the suspected sepsis group compared to the 
groups with CoNS-sepsis or other GPB-sepsis. However, the selection basis for including 
patients with negative blood cultures may have differed from our study and therefore the 
comparison might not be correct.  
In our study, the in-mortality of GNB-LOS was 25/34 (34%) and for the suspected –LOS 
group it was 12/74 (16%). The adjusted odds of dying before discharge were 3.9 times higher 
in the GNB-LOS group compared to the uninfected group. Due to the limited number of 
patients, the comparisons between GNB-LOS and the suspected sepsis group was not 
statistically significant.  
Recent research show that prolonged antibiotic treatment in preterm neonates without 
confirmed infection increases the risk for NEC, ROP, periventricular white matter damage 
and mortality (208). As long as a sufficient blood volume has been taken for the blood culture 
to ensure reliable results, it is of great importance that the neonatologist analyze the benefits 
and risk of every dose of antibiotics in situations when the blood-culture is negative.  
So, yes, suspected sepsis, and especially suspected-LOS, need further studies to determine 
whether it is a different entity and whether it might be treated with a different antibiotic 
strategy from culture proven sepsis. Many studies on EOS and treatment guidelines suggest 
stopping antibiotics within 36-48 hours in a culture-negative situation, unless there are strong 
clinical and biochemical indications not to do so (109, 209). The studies in this thesis do not 
oppose the recommendations from earlier studies that clinicians should trust negative blood 
cultures (109, 209).  
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6.10 How important is the clinical burden of ABR in NICUs in the Stockholm area?  
The invasive EPE in neonates were rare during the study period and not as high as we had 
expected (IV). During the EPE-outbreak 2008-2009, there were three neonates that died due 
to invasive ESBL-KP in combination with abdominal symptoms, intestinal 
perforation/necrotizing enterocolitis other major neonatal risk factors for mortality. Of all 107 
GNB isolates that have caused neonatal sepsis in the Stockholm area during an eleven year 
period, the proportion of multidrug-resistant invasive isolates strains is considered very low. 
This may well be the result of long-standing efforts in infection control and antimicrobial 
stewardship.  
A study of EPE carriage in Swedish pre-school children (Uppsala-region), shows a rapid 
increase in ESBL-carrier rates during the last decade. The prevalence of EPE-carriers in this 
group of societies increased from 2.6% to 16.8% during the time period from 2010 to 2016. 
Of all ESBL isolates, 58% were multi-resistant. No differences in antibiotic use in the area 
was seen (210). Even though the prevalence of invasive neonatal EPE-infections in Sweden is 
still rather low, there is no reason to believe that the EPE-prevalence will not increase among 
children. Travelling and immigration can explain the increase of ESBL-prevalence in Sweden 
(211). 
 
6.11 Which interventions can be done and to prevent LOS by ABR bacteria in 
neonates? 
Prevention of drug-resistant infection requires strict infection control protocols, avoidance of 
unnecessary use of broad-spectrum antibiotics, and also less invasive procedures in neonatal 
care (98, 122). Successful prevention protocols like the Matching Michigan initiative, with 
evidence-based strategies such as full-barrier precautions, avoidance of using the femoral 
route, prompt removal of catheters, hand hygiene, use of chlorhexidine skin antiseptics, did 
together with behavioral and cultural support, decreased the LOS due to venous catheters in 
19 pediatric ICUs in Great Britain (212). Surfactant administration and prenatal steroids 
reduce the risk for invasive procedures, such as mechanical ventilation, and therefore also 
reduces the risk for LOS (212, 213).  
An good exemplary model for reducing antibiotic use in a NICU in a HIC setting can be 
found in a recently published study in Lancet were the researchers conducted antibiotic 
stewardship strategies using surveillance and assessments of all antibiotic use. The overall 
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antibiotic use in the NICU decreased by 27% and there was no statistically significant 
differences in the safety outcomes between the baseline and intervention period (145).  
When the new intervention “Scrub the hub” was introduced in many of the Swedish neonatal 
wards whereby the membrane of the intravenous catheters were scrubbed with alcohol for 15 
seconds, LOS caused by CoNS was shown to be prevented (214). Respiratory viruses were, 
in contrast to gastro intestinal viruses, detected in a considerable number of suspected-LOS 
cases and should therefore not be forgotten in diagnosing the neonate with late-onset 
symptoms of infection (215). 
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7 CONCLUSIONS 
 
• A high proportion (56%) of the neonates, in a NICU in a tertiary hospital in Ecuador, 
were colonized with EPE. Two highly successful clones of KP, that are associated 
with spread of carbapenem resistance, were found. This finding was highly 
worrisome. The study was a good contribution to the collaborative work within the 
international and Latin American networks on antibiotic resistance. 
 
• BlaCTX-M 15 was the genotype of the ESBL spread at two NICUs at Karolinska 
University hospital (2008-2009). This is the ESBL that has been shown to be the most 
common genotype in Stockholm.  
 
• The children that were colonized during their NICU stay carried the same ESBL-KP 
for up to 26 months. The loss of EPE-colonization after two years seems to be related 
to the strain virulence, the environmental factors and the unique programming and 
development of the newborn microbiome. 
 
• There was no plasmid transfer between bacteria during the outbreak.  
 
• EPE-outbreaks need to be diagnosed rapidly. Optical DNA mapping is a reliable 
diagnostic tool in EPE-outbreaks in NICU-settings. 
 
• During a 11-year period, Gram-negative sepsis was rare but a great risk for neonatal 
mortality. GNB-LOS was associated with a higher neonatal mortality compared to 
uninfected controls, but not compared to suspected sepsis.  
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8 FUTURE 
There is currently a lot of new knowledge in the research field of infectious biology 
especially addressing the microbiome. In the field of neonatology, a clear definition of 
neonatal sepsis, taking into account the different age-dependent pathophysiologic responses 
preterm neonates, is required as a first step to enable the neonatologist to align to an adequate 
antibiotic treatment strategy.  
Antibiotic therapy for truly infected neonates is crucial and prospective clinical trials are 
needed to evaluate efficacy and safety of new antibiotics to treat ABR infections in neonates. 
Striving to achieve rational use of antibiotics in suspected sepsis, taking into account better 
rapid diagnostics and supporting the physicians to provide the most appropriate antibiotics, 
must continue.  
Therefore, studies on suspected sepsis need to be addressed. Prospective cohort studies, with 
an objective to initiate a surveillance of the microbiota before starting empiric antibiotics and 
during NICU-stay might guide the neonatologists to better understand how the changes in 
microbiota can precede onset of disease in the neonate.  
Within the neonatal sepsis study (IV), we also identified all neonates with confirmed GPB-
sepsis and the characteristics of these strains in terms of antibiotic susceptibility. This group 
would as well be interesting to study further in terms of pathogen specific LOS-mortality and 
resistance epidemiology.  
As a result of the multidisciplinary collaboration in the studies presented in this thesis, a 
project on antibiotic resistance in a NICU setting in Tanzania will be undertaken in the 
upcoming years in which ODM will be implemented in a format that is suitable for LMICs. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Neonatala infektioner utgör mer än en tredjedel av alla dödsfall i nyföddhetsperioden globalt 
sett. Blodförgiftning (sepsis) står för den största dödligheten och motsvarar ungefär en miljon 
neonatala dödsfall per år. Världshälsoorganisationen (WHO) prioriterar utvecklingen av 
antibiotikaresistens högt och betraktar det som ett av de största hälsohoten mot människors 
hälsa. Bakteriers förmåga att vara motståndskraftiga mot antibiotika kan ärvas men även 
överföras mellan bakterier om resistensgenen är lokaliserad på fria cirkulära DNA-molekyler 
(plasmider) i bakterien. Resistens-mekanismen hos de Gram-negativa tarmbakterier, som 
kallas Enterobacteriaceae, är förmågan att bilda Extended Spectrum Betalactamase (ESBL). 
ESBL är en grupp enzym som inaktiverar många typer av bred-spektrum antibiotika. 
Plasmid-medierad antibiotikaresistens är en stor del av ESBL-bildande Enterobacteriaceae 
(EPE )-stammars framgångsrika spridning över världen. Det finns anledning att vara oroad 
över antibiotikaresistensens utveckling och spridning i den del av vården där prematurfödda 
och nyfödda vårdas. De utgör är en grupp med särskild utsatthet och känslighet för bakteriella 
infektioner. Kolonisation innebär att bakterien bärs runt av sin värd men har inte gått över 
kroppens skyddsbarriär och orsakat en infektion. Infektioner orsakade av EPE hos både 
vuxna och barn är associerade med ökad dödlighet och sjuklighet. Lång sjukhusvård på 
neonatalavdelning är en riskfaktor för att utveckla bärarskap av EPE i de nyfödda barnets 
tarm, även om det vanligaste sättet för barnet att få EPE är att det överförs från modern i 
samband med förlossningen. Vetskapen är bristfällig avseende sambandet mellan 
kolonisation av EPE som man drabbats av under nyföddhetsperioden och senare infektioner 
orsakade av dessa. Erfarenheten kring hur kolonisation av EPE samt hur länge kolonisationen 
varar hos nyfödda är relativt liten. De studier som redovisat data avseende duration av EPE-
kolonisation i samhället är oftast utförda på vuxna patienter.  
Antibiotika är det mest använda läkemedlet på neonatalavdelningar. Antibiotikas verkan är 
livsnödvändig för att behandla ett nyfödd med sepsis men antibiotikas sidoeffekter på det 
nyfödda barnets tarmflora har visats kunna ge en obalans som. Detta kan i sin tur kan spela en 
icke gynnsam roll avseende det tidiga utvecklandet av barnets immunförsvar samt senare 
även i den framtida utvecklingen av kroniska sjukdomar.  
I detta avhandlingsarbete presenteras hur vanligt förekommande EPE-kolonisation i tarmen är 
hos nyfödda i Ecuador (studie I). Vi påvisade att 56 % av alla inneliggande nyfödda på 
neonatalavdelningen koloniserades med EPE under sin tid på avdelningen. Utav dessa EPE 
fanns en bakteriestam känd för att driva karbapenemresistens. I studie II-III följde vi barn 
som blivit EPE-koloniserade under ett fyra månader långt EPE-utbrott på två 
neonatalavdelningar i Stockholm under åren 2008-2009. Avföringsodlingar togs på 14 barn 
varannan månad upp till 26 månader och vid 5 år efter utskrivning gjordes ytterligare 
provtagning. Vi såg att 2/14 barn fortsatt bar samma bakteriestam vid 23 och 26 mån. Vi har 
använde Optimal DNA mapping, för att se att plasmiderna var identiska efter två års tid. Vid 
5 års ålder hade ett barn hade blivit återkoloniserat av en annan stam av EPE. 
Plasmidöverföring mellan bakterierstammar undersöktes men förekom ej. I studie IV 
undersöktes Gram-negativ sepsis med förmåga att bilda ESBL i Stockholm mellan åren 
2006-2016. Dödligheten var dock hög, 30 av 107 fall avled innan utskrivning men en låg 
andel av sepsisfallen berodde på EPE. 
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